TECHNICAL FIELD The present disclosure relates to pharmacologically active aryl piperazines, or pharmaceutically acceptable salts and esters thereof, as well as to pharmaceutical compositions comprising them and to their use as alpha2C antagonists. BACKGROUND OF THE INVENTION It is generally known and accepted in the art that compounds exhibiting alpha adrenergic activity may be used for the treatment of a wide variety of diseases and conditions of the peripheric system and the central nervous system (CNS). The alpha adrenergic receptors can be divided on a pharmacological basis into alpha1 and alpha2 adrenoceptors, which can both be further divided into subtypes. Three genetically encoded subtypes, namely alpha2A, alpha2B, and alpha2C adrenoceptors, have been discovered in human. A fourth pharmacologically defined subtype, namely alpha2D adrenoceptor, is known in some other mammals and in rodents. It corresponds to the genetically defined alpha2A adrenoceptor. The alpha2 adrenoceptor subtypes have distinct tissue distributions and functional roles. For instance, while alpha2A adrenoceptors are widely expressed in various tissues, alpha2C adrenoceptors are concentrated in the CNS and appear to play a role in the modulation of specific CNS mediated behavioral and physiological responses. Some compounds that are non-specific for any of the above-mentioned alpha2 subtypes and some compounds that are specific for certain alpha2 subtypes are known in the art. For example, atipamezole disclosed in EP 183 492 is a non-specific alpha2 antagonist. Compounds that are selective antagonists for the alpha2C subtype and are thus useful for the treatment of diseases of the central nervous system, are described, for example in WO 2009/013390 and WO 2010/058060. In order to be able to reduce the risk of adverse events during treatment, an enhanced selectivity of the alpha2 antagonists would be desirable. For example, the use of nonselective alpha2 antagonists is attributed with side effects, such as increases in blood pressure, heart rate, salivary secretion, gastrointestinal secretion, and anxiety. Also an enhanced potency of the alpha2C antagonists would be desirable, in order to be able to reduce the dose needed. DE 2241991 B2 discloses certain piperazinyl sydnonimide derivatives possessing hypotensive, vasodilatory and antianginous properties. SUMMARY OF THE INVENTION An object of the present disclosure is to provide novel alpha2C antagonists that can be used for the treatment of diseases or conditions of the peripheric or central nervous system wherein alpha2C antagonists are indicated to be useful. Accordingly, an object of the present disclosure is to provide further compounds to be used as alpha2C antagonists in the treatment of mammals. Furthermore, pharmaceutical compositions comprising the presently disclosed compounds are also provided. The alpha2 antagonists of the present disclosure have an improved selectivity for the alpha2C adrenoceptor subtype, an enhanced potency, improved metabolic stability, and/or improved solubility, moreover, more desirable pharmacokinetic and pharmacodynamics. DETAILED DESCRIPTION OF THE INVENTION The present disclosure relates to novel compounds having the general formula I, wherein A is a five membered unsaturated heterocyclic ring containing 1, 2 or 3 ring heteroatom(s) each independently selected from N, O and S, wherein said heterocyclic ring is unsubstituted, or said heterocyclic ring is substituted with 1 substituent Ri, or said heterocyclic ring is substituted with 2 substituents Ri and R2, or said heterocyclic ring is substituted with 3 substituents Ri, R2, and R3, or said heterocyclic ring is substituted with 4 substituents Ri, R2, Ri is (Ci-C )alkyl, (Ci-C )alkoxy, hydroxy(Ci-C )alkyl, (Ci-C )alkoxy(Ci-C )alkyl, (C C6)alkoxy-(C=0)-, CN, heterocyclyl, heterocyclyl-N-, or phenyl-N-, wherein said heterocyclyl or phenyl is optionally substituted with 1, 2, 3, or 4 substituent(s) each independently being (Ci-C 6)alkyl, (Ci- C6)alkoxy, oxo, or phenyl(Ci-C 6)alkoxy; R2 is (Ci-C 6)alkyl, (Ci-C 6)alkoxy, or (C1-C6)alkoxy(C1-C6)alkyl; R3 is (Ci-C 6)alkyl, (Ci-C 6)alkoxy, or (C1-C6)alkoxy(C1-C6)alkyl; R4 is (Ci-C 6)alkyl; R is H, or (Ci-C 6)alkyl; and R is H, or (Ci-C 6)alkyl; or Ri and R2 form, together with the ring atoms to which they are attached, a condensed 6 membered unsaturated heterocyclic ring, containing 1 or 2 heteroatom(s) being N; or a pharmaceutically acceptable salt or ester thereof; with the proviso that A is not l,2,3-oxadiazol-3-ium-3-yl. In one embodiment the present disclosure relates to compounds of formula I, wherein the com ound is a compound of formula la, In one embodiment the present disclosure relates to compounds of formula I, wherein is any one of the following groups (16) (17) ( 18) (19) (20) (2 1) (22) wherein Z is N, O or S; and atom marked with * is bonded to the parent molecular moiety. In one embodiment the present disclosure relates to compounds of formula I, wherein Ri is (Ci-C )alkyl, (Ci-C )alkoxy, hydroxy(Ci-C )alkyl, (Ci-C )alkoxy(Ci-C )alkyl, (C C6)alkoxy-(C=0)-, CN, phenyl-N-, or any one of the following groups ( ) (IO') wherein atom marked with * is bonded to the parent molecular moiety; and group ( 1') to ( 11') is optionally substituted with 1,2, 3, or 4 substituent(s) each independently being (Ci-C6)alkyl, (Ci-C6)alkoxy, oxo, or phenyl(Ci-C 6)alkoxy. In one embodiment the present disclosure relates to compounds of formula I, wherein ring A is any one of the groups (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), ( 11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), or (22), wherein group (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), ( 1 1), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), or (22) is unsubstituted, or group (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), ( 11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), or (22) is substituted with 1 substituent R or group (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), ( 11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), or (22) is substituted with 2 substituents Ri and R2, or group (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), ( 11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), or (22) is substituted with 3 substituents Ri, R2, and R3, or group (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), ( 11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), or (22) is substituted with 4 substituents Ri, R2, R3, and R4; Ri is (Ci-C )alkyl, (Ci-C )alkoxy, hydroxy(Ci-C )alkyl, (Ci-C )alkoxy(Ci-C )alkyl, (C C6)alkoxy-(C=0)-, CN, (Ci-C6)alkyl-(C=0)-, R R -, R 6(C=0)-R N-, phenyl-N -, or any one of the groups ( ), (2'), (3'), (4'), (5'), (6'), (7'), (8'), (9'), ( I O'), or ( 11'), wherein said phenyl or group (1'), (2'), (3'), (4'), (5'), (6'), (7'), (8'), (9'), (10'), or ( 11') is optionally substituted with 1,2, 3, or 4 substituent(s) each independently being (Ci- C6)alkyl, (Ci-C 6)alkoxy, oxo, or phenyl(Ci-C 6)alkoxy; R2 is (Ci-C 6)alkyl, (Ci-C 6)alkoxy, or (Ci-C 6)alkoxy(Ci-C6)alkyl; R3 is (Ci-C 6)alkyl, (Ci-C 6)alkoxy, or (Ci-C 6)alkoxy(Ci-C6)alkyl; R 4 is (Ci-C 6)alkyl; R is H, or (Ci-C 6)alkyl; and R is H, or (Ci-C 6)alkyl; or Ri and R2 form, together with the ring atoms to which they are attached, a condensed 6 membered unsaturated heterocyclic ring, containing 1 or 2 heteroatom(s) being N . In one embodiment the present disclosure relates to compounds of formula I, wherein ring A is any one of the groups (1), (2), (3), (4), (5), (6), (7), (8), (9), or (10) wherein group (1), (2), (3), (4), (5), (6), (7), (8), (9), or (10) is unsubstituted, or group (1), (2), (3), (4), (5), (6), (7), (8), (9), or (10) is substituted with 1 substituent R or group (1), (2), (3), (4), (5), (6), (7), (8), (9), or (10) is substituted with 2 substituents Ri and R2, or group (1), (2), (3), (4), (5), (6), (7), (8), (9), or (10) is substituted with 3 substituents R R2, and R3; Ri is hydroxy(Ci-C )alkyl, (Ci-C )alkoxy(Ci-C )alkyl, (Ci-C )alkoxy-(C=0)-, CN, (C C6)alkyl-(C=0)-, or any one of the groups ( ), (2'), (3'), (4'), (5'), (6'), (7'), (8'), (9'), or (10'), wherein group (1'), (2'), (3'), (4'), (5'), (6'), (7'), (8'), (9'), or (10'), is optionally substituted with 1,2, 3, or 4 substituent(s) each independently being (Ci-C 6)alkyl, ( -C6)alkoxy, oxo, or phenyl(Ci-C 6)alkoxy; R2 is (Ci-C )alkyl; R3 is (Ci-C 6)alkyl; R is H, or (Ci-C 6)alkyl; and R is H, or (Ci-C 6)alkyl; or Ri and R2 form, together with the ring atoms to which they are attached, a condensed 6 membered unsaturated heterocyclic ring, containing 1 heteroatom being N . In one embodiment the present disclosure relates to compounds of formula I, wherein ring A is any one of the groups (1), (2), (4), (7), (8), (9), or (10), wherein group (1), (2), (4), (7), (8), (9), or (10) is substituted with 1 substituent R or group (1), (2), (4), (7), (8), (9), or (10) is substituted with 2 substituents Ri and R2, or group (1), (2), (4), (7), (8), (9), or (10) is substituted with 3 substituents Ri, R2, and R3; Ri is (C1-C6)alkoxy(C1-C6)alkyl, or an one of the groups (2'), (4'), (5'), or (9'), wherein group (2'), (4'), (5'), or (9') is optionally substituted with 1,2, 3, or 4 substituent(s) each independently being (Ci-C6)alkyl or oxo; R2 is (Ci-C )alkyl; R3 is (Ci-C6)alkyl; R is (Ci-C6)alkyl; and R is (Ci-C6)alkyl. In one embodiment the present disclosure relates to compounds of formula I, wherein ring A is an one of the following groups Ri is hydroxy(Ci-C )alkyl, (Ci-C )alkoxy(Ci-C )alkyl, (Ci-C )alkoxy-(C=0)-, CN, (C C6)alkyl-(C=0)-, or any one of the groups ( ), (2'), (3'), (4'), (5'), (6'), (7'), (8'), (9'), or ( I O'), wherein group (1'), (2'), (3'), (4'), (5'), (6'), (7'), (8'), (9'), or ( I O'), is optionally substituted with 1,2, 3, or 4 substituent(s) each independently being (Ci-C6)alkyl, (Ci-C6)alkoxy, oxo, or phenyl(Ci-C 6)alkoxy; R2 is (Ci-C )alkyl; R3 is (Ci-C6)alkyl; R is H, or (Ci-C6)alkyl; and R is H, or (Ci-C6)alkyl; or Ri and R2 form, together with the ring atoms to which they are attached, a condensed 6 membered unsaturated heterocyclic ring, containing 1 heteroatom being N. In one embodiment the present disclosure relates to compounds of formula I, wherein ring is an one of the following groups Ri is R R6N-(C=0)- or any one of groups (2'), (4'), (5'), or (9'), wherein group (2'), (4'), (5'), or (9') is optionally substituted with 1,2, or 3 substituent(s) each independently being (Ci-C3)alkyl or oxo; R2 is (Ci-C3)alkyl; R3 is (Ci-C3)alkyl; R is (Ci-C3)alkyl; and R is (Ci-C3)alkyl. In one embodiment the present disclosure relates to compounds of formula I, wherein the compound is (S)- 1-(3-(4-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,5- dimethyl-lH-pyrazol-4-yl)-3,3-dimethylpyrrolidine-2,5-dione, (5)-2-(3-(4-((2,3- dihydrobenzo-[b] [1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- 1H-pyrazol-4- yl)isoindoline- 1,3-dione, (¾)-5-(4-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1 yl)-2-methyloxazole-4-carbonitrile, (¾)-l-(3-(4-((2,3-dihydrobenzo[b][l,4]dioxin-2- yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- lH-pyrazol-4-yl)azetidin-2-one, (¾)-3-(3-(4-((2,3- dihydrobenzo[b] [1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- 1H-pyrazol-4- yl)oxazolidin-2-one, (S)- 1-(3-(4-((2,3-dihydrobenzo[b][ 1,4]dioxin-2-yl)methyl)piperazin- 1- yl)- 1,5-dimethyl- lH-pyrazol-4-yl)-4,4-dimethylimidazolidin-2-one, (S)- 1-(3-(4-((2,3- dihydrobenzo[b] [1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- 1H-pyrazol-4-yl)- 3,4,4-trimethylimidazolidin-2-one, (5)-4-(4-((2,3-dihydrobenzo[b][l,4]dioxin-2- yl)methyl)piperazin- 1-yl)-5-(methoxymethyl)thiazole, (S)- 1-(3-(4-((2,3- dihydrobenzo[b] [1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- 1H-pyrazol-4- yl)imidazolidin-2-one, (S)- 1-((2,3-dihydrobenzo[b] [1,4]dioxin-2-yl)methyl)-4-( 1-(pyridin-2 yl)-lH-pyrazol-5-yl)piperazine, (5)-l-((2,3-dihydrobenzo[b][l,4]dioxin-2-yl)methyl)-4-(4- (methoxymethyl)-l,5-dimethyl-lH-pyrazol-3-yl)piperazine, (5)-ethyl 3-(4-((2,3- dihydrobenzo-[b] [1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- 1H-pyrazole-4- carboxylate, (5)-2-(3-(4-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,5- dimethyl-lH-pyrazol-4-yl)propan-2-ol, (S)-l-(3-(4-((2,3-dihydrobenzo[b][l,4]dioxin-2- yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- lH-pyrazol-4-yl)pyrrolidin-2-one, (S)- 1-(3-(4-((2,3- dihydrobenzo[b] [1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- 1H-pyrazol-4-yl)-3- methylimidazolidin-2-one, ( -N -(4-(4-((2,3-dihydrobenzo[b][l,4]dioxin-2- yl)methyl)piperazin- 1-yl)- 1,2,5-thiadiazol-3-yl)acetamide, (S)- 1-(4-(4-((2,3- dihydrobenzo[b][l,4]dioxin-2-yl)methyl)piperazin-l-yl)-l,2,5-thiadiazol-3-yl)-3,3- dimethylpyrrolidin-2-one, (5)-4-(4-((2,3-dihydrobenzo[b][l,4]dioxin-2-yl)methyl)piperazin- 1-yl)-N -(pyrimidin-2-yl)- 1,2,5-thiadiazol-3-amine, (S)-4-(4-((2,3- dihydrobenzo[b] [1,4]dioxin-2-yl)methyl)piperazin- 1-yl)-N -(pyrimidin-4-yl)- 1,2,5-thiadiazol- 3-amine, (S)- 1-(5-(4-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)thiazol-4- yl)pyrrolidin-2-one, 1-(4-(4-(((5)-2,3-dihydrobenzo[b] [1,4]dioxin-2-yl)methyl)piperazin- 1- yl)- 1,2,5-thiadiazol-3-yl)-3-methylpyrrolidin-2-one, (5)-2-(4-((2,3- dihydrobenzo[b][l,4]dioxin-2-yl)methyl)piperazin-l-yl)-l,3,4-thiadiazole, (5)-3-(4-((2,3- dihydrobenzo[b] [1,4]dioxin-2-yl)methyl)piperazin- 1-yl)-5-(methoxymethyl)- 1,2,4- oxadiazole, (S)- 1-(4-(4-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)-piperazin- 1-yl)- 1,2,5- thiadiazol-3-yl)pyrrolidin-2-one, (5)-l-(5-(4-((2,3-dihydrobenzo[b][l,4]-dioxin-2- yl)methyl)piperazin-l-yl)-l,3,4-thiadiazol-2-yl)imidazolidin-2-one, (5)-3-(4-(4-((2,3- dihydrobenzo[b] [1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,2,5-thiadiazol-3-yl)oxazolidin-2- one, (5)-4-(4-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,2,5- thiadiazole-3-carboxamide, (S)- 1-(4-(4-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2- yl)methyl)piperazin- 1-yl)- 1,2,5-thiadiazol-3-yl)-3-methylimidazolidin-2-one, (5)-4-(4-((2,3- dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)-N-methyl- 1,2,5-thiadiazole-3- carboxamide hydrochloride, (S)- 1-(4-(4-((2,3-dihydrobenzo[b] [1,4]dioxin-2- yl)methyl)piperazin- 1-yl)- 1,2,5-thiadiazol-3-yl)imidazolidin-2-one, (S)- 1-(5-(4-((2,3- dihydrobenzo[b][l,4]dioxin-2-yl)methyl)piperazin-l-yl)-3-methyl-isothiazol-4-yl)pyrrolidin- 2-one, (S)- 1-(4-(4-((2,3-dihydrobenzo[b] [1,4]dioxin-2-yl)methyl)-piperazin- 1-yl)-2- methylthiazol-5-yl)-3,3-dimethylpyrrolidine-2,5-dione hydrochloride, (5)-l-(4-(4-((2,3- dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,2,5-thiadiazol-3-yl)ethanone, (S)- 4-(4-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)-N,N -dimethyl- 1,2,5- thiadiazole-3-carboxamide, (S)-4-(4-((2,3-dihydrobenzo[b][l,4]dioxin-2- yl)methyl)piperazin- 1-yl)-N -(pyridin-4-yl)- 1,2,5-thiadiazol-3-amine dihydrochloride, (S)-3- (4-((2,3-dihydrobenzo-[b][l,4]dioxin-2-yl)methyl)piperazin-l-yl)isothiazolo[4,5-b]pyridine hydrochloride, ( -N -(2-(benzyloxy)pyridin-3-yl)-4-(4-((2,3-dihydrobenzo[b][l,4]-dioxin-2- yl)methyl)piperazin- 1-yl)- 1,2,5-thiadiazol-3-amine hydrochloride, (S)- 1-((2,3- dihydrobenzo[b][l,4]dioxin-2-yl)methyl)-4-(3-methyl-l-(pyridin-2-yl)-lH-pyrazol-5- yl)piperazine, (S)- 1-((2,3-dihydrobenzo[b] [1,4]dioxin-2-yl)methyl)-4-(1-(6-methoxypyridin- 2-yl)-3-methyl- lH-pyrazo 1-5 -yl)piperazine, or (5)-l-((2,3-dihydrobenzo[b][l,4]dioxin-2- yl)methyl)-4-(3-methyl- 1-(6-methylpyridin-2-yl)- 1H-pyrazol-5-yl)piperazine. In one embodiment the present disclosure relates to compounds of formula I, wherein the compound is or a pharmaceutically acceptable salt thereof. In one embodiment the present disclosure relates to compounds of formula I, wherein the compound is or a pharmaceutically acceptable salt thereof. In one embodiment the present disclosure relates to compounds of formula I, wherein the compound is or a pharmaceutically acceptable salt thereof. In one embodiment the present disclosure relates to compounds of formula I, wherein the compound is or a pharmaceutically acceptable salt thereof. In one embodiment the present disclosure relates to compounds of formula I, wherein the compound is or a pharmaceutically acceptable salt thereof. In one embodiment the present disclosure relates to compounds of formula I, wherein the compound is or a pharmaceutically acceptable salt thereof. In one embodiment the present disclosure relates to compounds of formula I, wherein the compound is or a pharmaceutically acceptable salt thereof. In one embodiment the present disclosure relates to compounds of formula I, wherein the compound is or a pharmaceutically acceptable salt thereof. In one embodiment the present disclosure relates to compounds of formula I, wherein the compound is or a pharmaceutically acceptable salt thereof. In one embodiment the present disclosure relates to compounds of formula I, wherein the compound is or a pharmaceutically acceptable salt thereof. In one embodiment the present disclosure relates to compounds of formula I wherein the compound is or a pharmaceutically acceptable salt thereof The terms employed herein have the meanings indicated below. The term "at least one" employed in the meanings below refers to one or several, such as one. The term "hydroxy", as employed herein as such or as part of another group, refers to a -OH group. The term "oxo", as employed herein as such or as part of another group, refers to a =0 group attached as a substituent. The term "(Ci-C 6)alkyl", as employed herein as such or as part of another group, refers to a saturated hydrocarbon group having a straight or branched moiety, containing 1, 2, 3, 4, 5 or 6 carbon atom(s). Representative examples of (Ci-Ce)alkyl include, but are not limited to, methyl, ethyl, n-propyl, z'so-propyl, n-butyl, z' -butyl, sec-butyl, tert-butyl, n-pentyl, z'so-pentyl, and n-hexyl. The term "(Ci-C 3)alkyl", as employed herein as such or as part of another group, refers to a saturated hydrocarbon group having a straight or branched moiety, containing 1, 2, or 3 carbon atom(s). Representative examples of (Ci-C3)alkyl include, but are not limited to, methyl, ethyl, n-propyl, and z'so-propyl. The term "( -C6)alkoxy", as employed herein as such or as part of another group, refers to an (Ci-C6)alkyl group, as defined herein, bonded to an oxygen atom. Representative examples of (Ci-C6)alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, n-butoxy, zso-butoxy, sec-butoxy, t rt-butoxy, 2,2-dimethylpropoxy, 3-methylbutoxy, and n-hexoxy. The term "hydroxy(Ci-C 6)alkyl", as employed herein as such or as part of another group, refers to at least one hydroxy group, as defined herein, bonded to a (Ci-C6)alkyl group, as defined herein. Representative examples of hydroxy(Ci-C6)alkyl include, but are not limited to, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2,2-dihydroxyethyl, 1-hydroxypropyl, 3-hydroxypropyl, 1-hydroxy- 1-methylethyl, and 1-hydroxy- 1-methylpropyl. The term "(Ci-C6)alkoxy(Ci-C6)alkyl", as employed herein as such or as part of another group, refers to at least one (Ci-C6)alkoxy group, as defined herein, bonded to an (Ci-C6)alkyl group, as defined herein. When there are several (d-C 6)alkoxy groups, the (Ci-Ce)alkoxy groups can be identical or different. Representative examples of (Ci-C6)alkoxy(Ci-C6)alkyl include, but are not limited to, methoxymethyl, ethoxymethyl, propoxymethyl, 2-methoxyethyl, 2-ethoxyethyl, 2,2-dimethoxyethyl, 1-methyl- 2-propoxyethyl, 1-methoxy- 1-methylethyl, and 4-methoxybutyl. The term "(Ci-C 6)alkyl-(C=0)", as employed herein as such or as part of another group, refers to a (Ci-C 6)alkyl group, as defined herein, bonded to a carbonyl group. Representative examples of (Ci-C 6)alkyl-(C=0) include, but are not limited to, acetyl, ethylcarbonyl, propylcarbonyl, and isopropylcarbonyl. The term "(Ci-C 6)alkoxy-(C=0)", as employed herein as such or as part of another group, refers to a ( -C6)alkoxy group, as defined herein, bonded to a carbonyl group. Representative examples of (Ci-C 6)alkoxy-(C=0) include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, and isopropoxycarbonyl. The term "phenyl(Ci-C 6)alkoxy", as employed herein as such or as part of another group, refers to a phenyl group, bonded to a (d-C 6)alkoxy group, as defined herein. Representative examples of phenyl(Ci-C6)alkoxy include, but are not limited to, phenylmethoxy, 2- phenylethoxy, and 3-phenylpropoxy. The term "heterocyclyl", as employed herein as such or as part of another group, refers to a 4, 5 or 6 membered saturated or unsaturated monocyclic group containing 1 or 2 ring heteroatom(s) each independently selected from N and O, or to a 9 or 10 membered saturated or unsaturated bicyclic group containing 1 or 2 ring heteroatom(s) each independently selected fromN and O. Representative examples of heterocyclyl include, but are not limited to azetidin-l-yl, pyrrolidin-l-yl, oxazolidin-3-yl, imidazolidin-l-yl, piperidin- 1-yl, morpholin-4-yl, pyrazol-l-yl, isoindolin-2-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, and pyrimidin-4-yl. The expression "compounds of the present disclosure" as employed herein refers to the compounds of formula I . The "pharmaceutically acceptable salts" according to the present disclosure include therapeutically active, non-toxic, base and and acid salt forms, which the compounds of formula I are able to form with both organic and inorganic bases and acids. Representative examples of pharmaceutically acceptable base addition salt forms, for example, metal or amine salts, include, but are not limited to, ammonium salts, lithium, sodium, potassium, calcium, magnesium, aluminum and zinc salts, salts with organic bases, such as N-methyl-Dglucamine, hydrabamine salts and salts with amino acids, such as arginine, lysine, and the like. Representative examples of pharmaceutically acceptable acid addition salts include, but are not limited to, chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, methane sulfonates, formates, tartrates, maleates, citrates, benzoates, salicylates, ascorbates, acetates and oxalates, fumarates, and succinates. Pharmaceutically acceptable esters, when applicable, may be prepared by known methods using pharmaceutically acceptable acids that are conventional in the field of pharmaceuticals and that retain the pharmacological properties of the free form. Non-limiting examples of these esters include esters of aliphatic or aromatic alcohols. Representative examples of pharmaceutically acceptable esters include, but are not limited to, methyl, ethyl, -propyl, zso-propyl, n-butyl, z -butyl, sec-butyl, tert-butyl, and benzyl esters. The present disclosure includes all the possible geometric isomers, for example cis and trans isomers, of the compounds of formula I, as well as all the possible optical isomers, such as diastereomers and enantiomers, of the compound of formula I . Furthermore, the present disclosure includes all the individual isomers and any mixtures thereof, such as racemic mixture. The individual isomers may be obtained using the corresponding isomeric forms of the starting materials or they may be separated after the preparation of the end compound according to conventional separation methods. For the separation of optical isomers, such as enantiomers, from the mixture thereof, conventional resolution methods, for example fractional crystallization or preparative chiral chromatography, may be used. Compounds of the invention can be prepared by a variety of synthetic routes analogously or according to the methods known in the literature using suitable starting materials. The starting materials used in the processes herein are either commercially available or can be prepared via synthetic routes known in the literature. In general, compounds of formula I can be prepared analogously or according to the following scheme 1: Scheme 1 For example, suitable starting materials containing the benzodioxane moiety are compounds of formula X: wherein L is a leaving group, e.g. halogen. Compounds of formula X can be prepared according to known methods. The other half in formula I, i.e. piperazine ring containing compounds of formula Y, can be prepared, for example, using the methods illustrated in Schemes 2, 3, 4 and 5. Scheme 2 In scheme 2, Ri is, for example, one of groups ( 1'), (2'), (3'), (4'), or (10'). Scheme 3 In scheme 3, Ri is some noncyclic moiety, such as alkoxy(Ci-C6)alkyl, hydroxy(Ci-C6)-alkyl, or (Ci-C )alkoxy-(C=0)-. Scheme 4 In scheme 4, the starting material W can be prepared, for example, as described in WO 2004/083235. In route 1, Ri is one of groups (2'), (3'), or (4'). In route 2, Ri is R N- or group (2'). In route 3, Ri is (C C6)alkyl-(C=0)- or R R6N-(C=0)-. In route 4, Ri is one of groups (6'), (7'), (8'), or (9'). Scheme 5 In sheme 5, Ri is group (6')· In schemes 2-5 groups (2'), (3'), (4'), (6'), (7'), (8'), (9'), (10'), R and are as defined above. A person skilled in the art realizes that any starting material or intermediate in the reactions described above can be protected, if necessary, in a manner known in the art. Any protected functionality can subsequently be deprotected in a manner known in the art. The synthetic routes described above are meant to illustrate the preparation of the compounds of formula I and the preparation is by no means limited thereto, that is, there are also other possible synthetic methods which are within the general knowledge of a person skilled in the art. The compounds of formula I may be converted, if desired, into their pharmaceutically acceptable salt or ester form using methods known in the art. The present disclosure will be explained in more detail by the following examples. The examples are meant for illustrating purposes only and do not limit the scope of the invention defined in the claims. Normal phase and reverse phase flash chromatography was performed using CombiFlash instruments together with disposable Redisep columns (Teledyne ISCO). Preparative HPLC purifications were performed with a Waters preparative HPLC/MS autopurification system equipped with an XBridge Prep C18 (5mih, 30 x 150 mm) column. Typically, a gradient of water/acetonitrile with 0.1% formic acid was used as eluent. Microwave heating was performed using microwave reactors from Biotage. The structures of the products were confirmed by 1H NMR. The spectra were measured with a Bruker Avance 400 instrument. LC-MS analyses were performed using a Waters Acquity UPLC/MS/MS with an TQ detector. For the chiral HPLC analysis, Agilent 1100-series HPLC instrument equipped with diode array detector was used. The following general abbreviations are used: EtOAc = ethyl acetate, TFA = trifluoroacetic acid, ACN = acetonitrile, EtOH = ethanol, AcOH = acetic acid, IPA = isopropyl alcohol, DMSO-de = deuterated dimethyl sulfoxide, CDC13 = deuterated chloroform, DIPEA = N,Ndisopropylethylamine, DCM = dichloromethane, DMF = N,N-dimethylformamide, MeOH = methanol, THF = tetrahydrofuran, TBAF = tetrabutylammonium fluoride, TBDMS-C1 = tertbutyldimethylsilyl chloride, HC1 = hydrochloric acid, PCC = pyridinium chloro-chromate, MTBE = methyl t r t-butyl ether, Pd/C = palladium on carbon, Pd2(dba) = tris- (dibenzylideneacetone)dipalladium(O), RuPhos = 2-dicyclohexylphosphino-2',6'- diisopropoxybiphenyl, LiHMDS = lithium hexamethyldisilazide, DMAP = 4-dimethylaminopyridine, (Boc O = di-t r t-butyl dicarbonate, NMP = N-methyl-2-pyrrolidone, TEA = triethylamine, EDC HC1 = l-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, LAH = lithium aluminum hydride, RT = room temperature, MW = microwave, LC-MS = liquid chromatography - mass spectrometry, HPLC = high performance liquid chromatography. Preparation of the compounds of the present disclosure General procedure Al Piperazin-l-yl derivative ( 1 eq.) was dissolved in ACN. DIPEA ( 1 eqv) was added, followed by addition of K2C0 3 (1.5 eqv) and (2i?)-2-(bromomethyl)-2,3-dihydro-l,4-benzodioxin (1- 1.4 eqv). The vial was flushed with nitrogen and sealed. The reaction mixture was heated in the microwave at 120°C for 4 hours. The solvents were removed under reduced pressure. The procedure could be performed with only DIPEA or K2C0 3 as a base. General procedure A2 Piperazin-l-yl derivative ( 1 eq.) was dissolved in DMF under nitrogen. (2R)- 2- (bromomethyl)-2,3-dihydro-l,4-benzodioxin or (1-1.4 eq.) and Na2C0 3 or K2C0 3 (1.5-2.5 eq.) were added and the reaction mixture was heated at 100-120 °C for 3-4 h. The reaction mixture was allowed to cool down to RT and 1M HCl-solution was added. The mixture was extracted with MTBE. The pH of the water phase was adjusted to 10 with Na2C0 3 and then extracted with EtOAc. The EtOAc phase was washed with brine and concentrated under reduced pressure. EXAMPLE 1: (S)-l-(3-(4-((2,3-Dihydrobenzo[b] [l,4]dioxin-2-yl)methyl)piperazin-lyl)- l,5-dimethyl-lH-pyrazol-4-yl)-3,3-dimethylpyrrolidine-2,5-dione Step 1: l,5-Dimethyl-3,4-dinitro-lH-pyrazole To a solution of 100% H2S0 4 (30 ml) was added Fuming HN0 3 (30 ml) at 0°C, and then stirred at 0°C for 15 min. 1,5-Dimethyl-lH-pyrazole (10.0 g, 104.02 mmol) was added at 0°C during 30 min. The resulting reaction mixture was warmed to RT and heated to 100°C for 6 h. The reaction mixture was cooled down and poured into ice and the resulting mixture was stirred overnight. The precipitate (7.0 g) was filtered, washed with water and dried in vacuum. The crude product was used for next step without further purification. Step 2 : tert- ty 4-(l,5-dimethyl-4-nitro-lH-pyrazol-3-yl)piperazine-l-carboxylate To a solution of l,5-dimethyl-3,4-dinitro-lH-pyrazole (7.0 g, 37.6 mmol) in isopropanol (150 ml) was added 1-Boc piperazine (21.0 g, 112.88 mmoL) at RT and the resulting reaction mixture was heated to 140°C for 48 h. The reaction mixture was concentrated under reduced pressure. The product was purified by flash column using 2% MeOH/DCM as eluent to afford 3.3 g of pale yellow solid. LC-MS (ES+) [M+l]: 326.2 Step 3 : tert-Butyl 4-(4-amino-l,5-dimethyl-lH-pyrazol-3-yl)piperazine-l-carboxylate To a solution of tert-butyl 4-(l,5-dimethyl-4-nitro-lH-pyrazol-3-yl)piperazine-l-carboxylate (3.0 g, 9.23 mmol) in THF: MeOH (1:1) (25 ml) was added H20 (5 ml), Fe (3.1 g, 55.38 mmol) and NH4C 1 (2.96 g, 55.38 mmol) at RT, and the resulting reaction mixture was stirred at 70°C for 4 h. The reaction mixture was filtered and filtrate was concentrated under reduced pressure. The product was purified by flash column using 3% MeOH/DCM as eluent to afford 2.0 g of as pale brown solid. LC-MS (ES+) [M+l]: 296.2 Step 4 : tert-Buty\ 4-(4-(3,3-dimethyl-2,5-dioxopyrrolidin-l-yl)-l,5-dimethyl-lHpyrazol- 3-yl)piperazine-l-carboxylate To a solution of tert-butyl 4-(4-amino-l,5-dimethyl-lH-pyrazol-3-yl)piperazine-lcarboxylate (1.0 g, 3.38 mmol) in toluene (30 ml) was added Et N (0.71 ml, 5.01 mmol) and 3,3-dimethyldihydrofuran-2,5-dione (0.52 g, 4.06 mmol) at RT. The resulting reaction mixture was heated at 100° C for 4h. The reaction mixture was concentrated and water water was added. It was then extracted with EtOAc. The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure to obtain crude product. The product was purified by Combi flash using 3%MeOH/DCM as eluent to afford 0.7 g of pale yellow solid. LC-MS (ES+) [M+l]: 406.3 Step 5: l-(l,5-Dimethyl-3-(piperazin-l-yl)-lH-pyrazol-4-yl)-3,3-dimethylpyrrolidine- 2,5-dione hydrochloride To a solution of tert-butyl 4-(4-(3,3-dimethyl-2,5-dioxopyrrolidin-l-yl)-l,5-dimethyl-lHpyrazol- 3-yl)piperazine-l-carboxylate (0.7 g, 1.73 mmol) in 1,4-Dioxane (5 ml) was added 1,4-Dioxane-HCl (4 M, 30 ml) at 0 C and stirred at RT for 4h. The reaction mixture was concentrated under reduced pressure. The product was purified by trituration with n-pentane and diethyl ether to afford 0.43 g of yellow solid. LC-MS (ES+) [M+l]: 306.0 Step 6: (5)-l-(3-(4-((2,3-Dihydrobenzo[b] [l,4]dioxin-2-yl)methyl)piperazin-l-yl)-l,5- dimethyl-lH-pyrazol-4-yl)-3,3-dimethylpyrrolidine-2,5-dione (S)- 1-(3-(4-((2,3-Dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- 1Hpyrazol- 4-yl)-3,3-dimethylpyrrolidine-2,5-dione was prepared according to the general procedure Al using l-(l,5-dimethyl-3-(piperazin-l-yl)-lH-pyrazol-4-yl)-3,3- dimethylpyrrolidine-2,5-dione, HC1 (100 mg, 0.293 mmol), DIPEA (0.051 ml, 0.293 mmol), K2C0 3 (60.6 mg, 0.439 mmol), (2R)- 2-(bromomethyl)-2,3-dihydro-l,4-benzodioxin (67.0 mg, 0.293 mmol) and ACN ( 1.4 ml). The product was purified by flash chromatography using 2% MeOH in DCM as eluent to afford 5 1 mg of oil. LC-MS (ES+) [M+l]: 454.2, 1H NMR (400 MHz, CDC13) d ppm 1.36 - 1.49 (m, 6H) 1.92 - 2.04 (m, 3H) 2.5 1 - 2.68 (m, 6H) 2.69 - 2.73 (m, 2H) 2.97 - 3.16 (m, 4H) 3.62 - 3.73 (m, 3H) 3.90 - 4.06 (m, 1H) 4.21 - 4.37 (m, 2H) 6.75 - 6.96 (m, 4H). EXAMPLE 2 : (5)-2-(3-(4-((2,3-Dihydrobenzo[b] [l,4]dioxin-2-yl)methyl)piperazin-lyl)- 1,5-dimethyl- lH-pyrazol-4-yl)isoindoline- 1,3-dione Step 1: tert-Butyl 4-(4-(l,3-dioxoisoindolin-2-yl)-l,5-dimethyl-lH-pyrazol-3- yl)piperazine-l-carboxylate tert-Butyl 4-(4-( 1,3-dioxoisoindolin-2-yl)- 1,5-dimethyl- 1H-pyrazol-3 -yl)piperazine- 1- carboxylate was prepared as in intermediate example 1 step 4 using tert-butyl 4-(4-aminol, 5-dimethyl-lH-pyrazol-3-yl)piperazine-l-carboxylate(1.5 g, 5.08 mmol), Phallic anhydride (0.9 g, 6.09 mmol), Et N (1.06 ml, 7.62 mmol) and toluene (40 ml). The product was purified by Combi flash using 3% MeOH in DCM as eluent to afford 800 mg of pale yellow solid. LC-MS (ES+) [M+l]: 426.2 Step 2: 2-(l ,5-Dimethyl-3-(piperazin- 1-yl)-lH-pyrazol-4-yl)isoindoline- 1,3-dione hydrochloride 2-(l,5-Dimethyl-3-(piperazin-l-yl)-lH-pyrazol-4-yl)isoindoline-l,3-dione hydrochloride was prepared as in intermediate example 1 step 5 using tert-butyl 4-(4-(l,3-dioxoisoindolin-2-yl)- l,5-dimethyl-lH-pyrazol-3-yl)piperazine-l-carboxylate (0.8 g, 1.88 mmol), 1,4-dioxane-HCl (4 M, 30 ml) and 1,4-dioxane (5 ml). The product was purified by trituration with n-pentane and diethyl ether to afford 0.45 g of pale yellow solid. LC-MS (ES+) [M+l]: 326.0 Step 3 : (5)-2-(3-(4-((2,3-Dihydrobenzo[b][l,4]dioxin-2-yl)methyl)piperazin-l-yl)-l,5- dimethyl-lH-pyrazol-4-yl)isoindoline- 1,3-dione (5)-2-(3-(4-((2,3-Dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- 1Hpyrazol- 4-yl)isoindoline-l,3-dione was prepared according to the general procedure Al using 2-(l,5-dimethyl-3-(piperazin-l-yl)-lH-pyrazol-4-yl)isoindoline-l,3-dione, HC1 (100 mg, 0.276 mmol), (2R)- 2-(bromomethyl)-2,3-dihydro-l,4-benzodioxin (63.3 mg, 0.276 mmol), DIPEA (0.048 ml, 0.276 mmol), K2C0 3 (57,3mg, 0.415 mmol) and ACN (1.4 ml). The product was purified by flash chromatography using 2% MeOH in DCM as eluent to afford 64 mg of yellowish oil. LC-MS (ES+) [M+l]: 474.2, 1H NMR (400 MHz, CDC13) d ppm 1.96 - 2.09 (m, 3H) 2.43 - 2.72 (m, 6H) 3.1 1 (t, 4H) 3.70 (s, 3H) 3.86 - 4.01 (m, 1H) 4.17 - 4.35 (m, 2H) 6.73 - 6.92 (m, 4H) 7.74 - 7.88 (m, 2H) 7.89 - 8.02 (m, 2H). EXAMPLE 3 : S>5-(4-((2,3-Dihydrobenzo[b] [l,4]dioxin-2-yl)methyl)piperazin-l-yl)- 2-methyloxazole-4-carbonitrile Step 1: 2-Amino-3,3-dichloroacrylonitrile To an ice cold stirred solution of 2,2-dichloroacetonitrile (5.0 g, 45.47 mmol) and acetone cyanohydrin (4.56 ml, 50.03 mol) in a mixture of Et20 and ACN (25 ml, 1:4) was added KCN (60 mg, 0.909 mmol) and stirred at 0°C for 10 h. Solvent was evaporated under reduced pressure. Et20 (15 ml) and activated charcoal (300 mg) was added and the mixture was stirred for 10 mins, filtered through a pad of celite and washed with Et20 (5 ml). The filtrate was concentrated under reduced pressure to obtain 4.1 g of brown solid. Step 2 : N-(2,2-dichloro-l-cyanovinyl)acetamide A solution of 2-amino-3,3-dichloroacrylonitrile (4.0 g, 29.20 mmol) in a mixture of acetic anhydride (5.51 ml, 58.41 mmol) and acetic acid (0.08 ml, 1.46 mmol) was allowed to stir at RT for 16 h. Reaction mixture was diluted with DCM (200 ml) and washed with water (2 x 100 ml). The organic layer was dried over anhydrous Na2S0 4 and under reduced pressure. The product was purified by triturating with cold Et20 to obtain 3.6 g of light brown solid. Step 3 : tert- ty 4-(4-cyano-2-methyloxazol-5-yl)piperazine-l-carboxylate To an ice cold stirred solution of N-(2,2-dichloro-l-cyanovinyl)acetamide (4.5 g, 25.14 mmol) in ACN (100 ml) was added Et N (7.0 ml, 50.28 mmol) and tert-b y piperazine-1- carboxylate (5.6 g, 30.17 mmol) and stirred at RT for 16 h. Solvent was evaporated under reduced pressure. The residue was diluted with EtOAc (400 ml) and washed with 10% aqueous NaHC0 3 solution (2 x 100 ml). The organic layer was dried over anhydrous Na2S0 4 and concentrated under reduced pressure. The product was purified by column chromatography on silica gel 100-200 mesh and eluted with 40% EtOAc in pet ether to obtain 2.1 g of off-white solid. LC-MS (ES+) [M+l]: 293.2 Step 4 : 2-Methyl-5-(piperazin-l-yl)oxazole-4-carbonitrile hydrochloride To a solution of tert-b y 4-(4-cyano-2-methyloxazol-5-yl)piperazine-l-carboxylate (0.549 g, 1.88 mmol) in EtOAc (10 ml) was added 1,4-dioxane-HCl (4 M, 2.3 ml) and the reaction mixture was stirred overnight. The solvents were evaporated under reduced pressure and the product was purified by trituration with MTBE to afford 340 mg of white solid. LC-MS (ES+) [M+l]: 193.1 Step 5: S>5-(4-((2,3-Dihydrobenzo[b] [l,4]dioxin-2-yl)methyl)piperazin-l-yl)-2- methyloxazole-4-carbonitrile (¾^-5-(4-((2,3-Dihydrobenzo[b][l,4]dioxin-2-yl)methyl)piperazin-l-yl)-2-methyloxazole-4- carbonitrile was prepared according to the general procedure Al using 2-methyl-5- (piperazin-l-yl)oxazole-4-carbonitrile, HC1 (150 mg, 0.655 mmol), ftR)- 2-(bromomethyl)- 2,3-dihydro-l,4-benzodioxin (150 mg, 0.655 mmol), DIPEA (0.1 14 ml, 0.655 mmol), K2C0 3 (136 mg, 0.982 mmol) and ACN (1.4 ml). The product was purified by flash chromatography using 10-70 % gradient of EtOAc in heptane to afford 82 mg of colourless oil. LC-MS (ES+) [M+l]: 342.2, 1H NMR (400 MHz, CDC13) d ppm 2.34 (s, 3H) 2.58 - 2.84 (m, 6H) 3.50 - 3.63 (m, 4H) 3.97 - 4.09 (m, 1H) 4.25 - 4.39 (m, 2H) 6.77 - 6.96 (m, 4H). EXAMPLE 4 : S>l-(3-(4-((2,3-Dihydrobenzo[b] [l,4]dioxin-2-yl)methyl)piperazin-lyl)- 1,5-dimethyl-lH-pyrazol-4-yl)azetidin-2-one Step 1: Ethyl 3-oxopropanoate To a stirred solution of ethyl 3,3-diethoxypropanoate (2.0 g, 10.51 mmol) in THF (5.0 ml) was added 4.0 M HC1 (20.0 ml) at 0°C. After the addition, the reaction mixture was warmed to RT and stirred for 8 h. The reaction mixture was diluted with diethyl ether and organic layer was dried over Na2S0 4, concentrated under reduced pressure to obtain 0.3 g of colourless oil. The crude product was used for next step without further purification. Step 2 : tert-Buty\ 4-(4-((3-ethoxy-3-oxopropyl)amino)-l,5-dimethyl-lH-pyrazol-3- yl)piperazine-l-carboxylate t r t-Butyl 4-(4-((3 -ethoxy-3 -oxopropyl)amino)- 1,5-dimethyl- 1H-pyrazol-3 -yl)piperazine- 1- carboxylate was prepared as in intermediate example 3 step 3 using tert-butyl 4-(4-aminol, 5-dimethyl-lH-pyrazol-3-yl)piperazine-l-carboxylate (3.0 g, 10.17 mmol) ethyl 3- oxopropanoate (1.18 g, 10.17 mmol), NaCNBH (0.96 g, 15.25 mmol) and 1, 2-dichloro ethane (100 ml). The product was purified by column chromatography using 100-200 mesh silica gel and eluted on 2% MeOH/DCM. to afford 1.2 g of brown liquid. LC-MS (ES+) [M+l]: 396.3 Step 3 : tert-Butyl 4-(l,5-dimethyl-4-(2-oxoazetidin-l-yl)-lH-pyrazol-3-yl)piperazine-lcarboxylate To a solution of tert-butyl 4-(4-((3-ethoxy-3-oxopropyl)amino)-l,5-dimethyl-lH-pyrazol-3- yl)piperazine-l -carboxylate (1.5 g, 3.79 mmol) in dry THF (25.0 ml) was added MeMgBr (3.0 M in diethylether (1.9 ml) at 0 °C. The reaction mixture was stirred at RT for 8 h. The reaction mixture was quenched with NH4C1, then extracted with EtOAc. The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The product was purified by column chromatography using 100-200 mesh silica gel and eluted on 2% MeOH/DCM to afford 0.13 g of brown solid. LC-MS (ES+) [M+l]: 350.3 Step 4 : l-(l,5-Dimethyl-3-(piperazin-l-yl)-lH-pyrazol-4-yl)azetidin-2-one TFA To a solution of tert-butyl 4-(l,5-dimethyl-4-(2-oxoazetidin-l-yl)-lH-pyrazol-3- yl)piperazine-l -carboxylate (0.37 g, 1.06 mmol) in DCM (5.0 ml) was added TFA (0.35 ml) at 0 °C and allowed to stir at RT for 16 h. The reaction mixture was concentrated under reduced pressure. The product was purified by trituration with n-pentane to afford 0.360 g of pale brown liquid. LC-MS (ES+) [M+l]: 250.1 Step 5: S>-l-(3-(4-((2,3-Dihydrobenzo[b][l,4]dioxin-2-yl)methyl)piperazin-l-yl)-l,5- dimethyl-lH-pyrazol-4-yl)azetidin-2-one (S)- 1-(3-(4-((2,3-Dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- 1Hpyrazol- 4-yl)azetidin-2-one was prepared according to the general procedure Al using 1- (l,5-dimethyl-3-(piperazin-l-yl)-lH-pyrazol-4-yl)azetidin-2-one, TFA (200 mg, 0.700 mmol), ftR)- 2-(bromomethyl)-2,3-dihydro-l,4-benzodioxin (160 mg, 0.700 mmol), DIPEA (0.122 ml, 0.700 mmol), K2C0 3 (145 mg, 1.050 mmol) and ACN (4 ml). The product was purified by flash chromatography using 2-4 % gradient of MeOH in DCM as eluent to afford 7 1 mg of oil. LC-MS (ES+) [M+l]: 396.2, 1H NMR (400 MHz, CDC13) d ppm 2.15 (s, 3H) 2.54 - 2.77 (m, 6H) 3.01 - 3.24 (m, 6H) 3.44 - 3.54 (m, 2H) 3.59 (s, 3H) 3.95 - 4.13 (m, 1H) 4.23 - 4.42 (m, 2H) 6.76 - 6.97 (m, 4H). EXAMPLE 5: S>3-(3-(4-((2,3-Dihydrobenzo[b] [l,4]dioxin-2-yl)methyl)piperazin-lyl)- 1,5-dimethyl- lH-pyrazol-4-yl)oxazolidin-2-one Step 1: (Allyloxy)(tef"f-butyl)dimethylsilane To an ice cold stirred solution of prop-2-en-l-ol (10 g, 172.41 mmol) in DMF (100 ml) were added imidazole (23.4 g, 344.82 mmol) and TBDMS-C1 (31.1 g, 206.89 mmol). The reaction mixture was stirred at RT for 16 h. The reaction mixture was quenched with water (600 ml) and extracted with diethyl ether (2 x 300 ml). The combined organic layer was washed with water and brine. The organic layer was dried over anhydrous Na2S0 4 and concentrated under reduced pressure to obtain 15.0 g of oil. The crude product was used for next step without further purification. Step 2 : 2-((tert-Butyldimethylsilyl)oxy)acetaldehyde To a solution of (allyloxy)(t rt-butyl)dimethylsilane (1.0 g, 172.31 mmol) in diethyl ether and t-BuOH was added NaI0 4 in water at room temperature followed by Os0 4 (0.02 M in water) at 0°C. The resulting reaction mixture was stirred at room temperature for 3 h. The reaction mixture was quenched with a2S03 at 0°C and extracted with diethyl ether (2 x 20 ml). The combined organic extracts were washed with water and brine. The organic layer was dried over anhydrous Na2S0 4 and concentrated under reduced pressure to obtain 1.0 g of crude product as liquid. The crude product was used for next step without further purification. Step 3 : tert- ty 4-(4-((2-((tei-i-butyldimethylsilyl)oxy)ethyl)amino)-l,5-dimethyl-lHpyrazol- 3-yl)piperazine-l-carboxylate To an ice cold stirred solution of tert-b y 4-(4-amino-l,5-dimethyl-lH-pyrazol-3- yl)piperazine-l-carboxylate (100 mg, 0.338 mmol) in 1, 2-dichloro ethane (5.0 ml) was added 2-((t rt-butyldimethylsilyl)oxy)acetaldehyde (58 mg, 3.389 mmol) and stirred for 10 min. NaBH(OAc)3 (143 mg, 0.677 mmol) was added to reaction mixture in portions and reaction was stirred at room temperature for 16 h The reaction mixture was diluted with DCM, washed with water and brine. The organic layer was dried over anhydrous Na2S0 4 and concentrated under reduced pressure. The product was purified by flash column using ethyl acetate in pet ether as eluent to obtain 50 mg of the desired product. LC-MS (ES+) [M+l]: 454.4 Step 4 : tert-Butyl 4-(4-((2-hydroxyethyl)amino)-l,5-dimethyl-lH-pyrazol-3- yl)piperazine-l-carboxylate To an ice cold stirred solution of tert-butyl 4-(4-((2 -((t r t-butyldimethylsilyl)oxy)ethyl)- amino)-l,5-dimethyl-lH-pyrazol-3-yl)piperazine-l-carboxylate (0.87 g, 1.92 mmol) in THF (10 ml) was added TBAF (2.88 ml, 2.88 mmol) and stirred at 0°C®RT for 2 h. The reaction mixture was diluted with EtOAc, washed with water and brine. The organic layer was dried over anhydrous Na2S0 4 and concentrated under reduced pressure. The product was purified by flash column using ethyl acetate in pet ether as eluent to obtain 520 mg of the desired product. LC-MS (ES+) [M+l]: 340.3 Step 5: tert-Butyl 4-(l,5-dimethyl-4-(2-oxooxazolidin-3-yl)-lH-pyrazol-3-yl)piperazine- 1-carboxylate To a solution of tert-butyl 4-(4-((2-hydroxyethyl)amino)-l,5-dimethyl-lH-pyrazol-3- yl)piperazine-l-carboxylate (1.0 g, 2.949 mmol) in dry DMF (10 ml) were added DIPEA (2. 11 ml, 11.799 mmol) and CDI ( 1.43 g, 8.849 mmol) at RT in a seal tube. The reaction mixture was heated to 100°C for 16 h. The reaction mixture was quenched with water (80 ml) and extracted with EtOAc (2 x 60 ml). The combined organic extracts were washed with water, brine. The organic layer was dried over anhydrous Na2S0 4 and concentrated under reduced pressure. The product was purified by combi-flash using ammonium acetate in water and MeOH as eluent to obtain 440 mg of solid. LC-MS (ES+) [M+l]: 366.2 Step 6: 3-(l,5-Dimethyl-3-(piperazin-l-yl)-lH-pyrazol-4-yl)oxazolidin-2-one hydrochloride 3-(1,5-Dimethyl-3-(piperazin- 1-yl)- 1H-pyrazol-4-yl)oxazolidin-2-one hydrochloride was prepared as in intermediate example 1 step 5 using tert-butyl 4-(l,5-dimethyl-4-(2- oxooxazolidin-3-yl)-lH-pyrazol-3-yl)piperazine-l-carboxylate (400 mg, 1.095 mmol) and 1,4-dioxane-HCl (4 M, 20 ml). The product was purified purified by trituration with npentane to afford 330 mg of yellow solid. LC-MS (ES+) [M+l]: 266.3 Step 7: S>3-(3-(4-((2,3-Dihydrobenzo[b] [l,4]dioxin-2-yl)methyl)piperazin-l-yl)-l,5- dimethyl-lH-pyrazol-4-yl)oxazolidin-2-one fS>3-(3-(4-((2,3-Dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- 1Hpyrazol- 4-yl)oxazolidin-2-one was prepared according to the general procedure A2 using 3- (l,5-dimethyl-3-(piperazin-l-yl)-l H-pyrazol-4-yl)oxazolidin-2-one, HC1 (132 mg, 0.437 mmol), (2R)- 2-(bromomethyl)-2,3-dihydro-l,4-benzodioxin (100 mg, 0.437 mmol), Na2C0 3 (69.4 mg, 0.655 mmol) and DMF (2 ml). The product was purified by reversed phase flash chromatography using 0.1% HCOOH/ ACN as eluent to afford 53.4 mg of white solid. LCMS (ES+) [M+l]: 414.2, 1H NMR (400 MHz, CDC13) d ppm 2.13 (s, 3H) 2.50 - 2.85 (m, 6H) 3.06 - 3.30 (m, 4H) 3.63 (s, 3H) 3.78 - 3.91 (m, 2H) 4.02 (dd, 1H) 4.25 - 4.42 (m, 2H) 4.43 - 4.54 (m, 2H) 6.78 - 6.94 (m, 4H). EXAMPLE 6: (5)-l-(3-(4-((2,3-Dihydrobenzo[b][l,4]dioxin-2-yl)methyl)piperazin-lyl)- 1,5-dimethyl-lH-pyrazol-4-yl)-4,4-dimethylimidazolidin-2-one Step 1: Benzyl (l-hydroxy-2-methylpropan-2-yl)carbamate To a stirred solution of 2-amino-2-methylpropan-l-ol (3.0 g, 33.65 mmol) in DCM (200 ml) was added aqueous NaHC0 3 (8.4 g, 100.95 mmol in 100 ml water) at 0°C and 50% wt- CbzCl in toluene ( 11.4 g, 33.65 mmol) was added drop wise over 15 min. After the addition, the reaction mixture was warmed to RT and stirred for 16 h. The reaction mixture was diluted with DCM and organic layer was dried over Na2S0 4, concentrated under reduced pressure. The product was purified by flash column using 20%> ethyl acetate in pet ether as eluent to afford 4.2 g of colorless oil. LC-MS (ES+) [M+l]: 224.2 Step 2 : Benzyl (2-methyl-l-oxopropan-2-yl)carbamate To a stirred solution of benzyl (l-hydroxy-2-methylpropan-2-yl)carbamate (4.0 g, 17.91 mmol) in DCM (40.0 ml) was added PCC (7.72 g, 35.83 mmol) and silica gel (10.0 g) at 0°C and then stirred at RT for 16 h. The reaction mixture was diluted with DCM and filtered through Celite pad; the filtrate was concentrated under reduced pressure. The product was purified by flash column using 20% ethyl acetate in pet ether as eluent to afford 2.1 g of pale yellow liquid. LC-MS (ES+) [M+l]: 222.2 Step 3 : tert-Butyl 4-(4-((2-(((benzyloxy)carbonyl)amino)-2-methylpropyl)amino)-l,5- dimethyl-lH-pyrazol-3-yl)piperazine-l-carboxylate tert-Butyl 4-(4-((2-(((benzyloxy)carbonyl)amino)-2-methylpropyl)amino)-l,5-dimethyl-lHpyrazol- 3-yl)piperazine-l-carboxylate was prepared as in intermediate example 3 step 3 using tert-butyl 4-(4-amino-l,5-dimethyl-lH-pyrazol-3-yl)piperazine-l-carboxylate (1.5 g, 5.08 mmol), benzyl (2-methyl-l-oxopropan-2-yl)carbamate (1.12 g, 5.08 mmol) NaBH(OAC) 3 (2.15 g, 10.17 mmol) and 1, 2-dichloro ethane (50 ml). The product was purified by column chromatography using 100-200 mesh silica gel and eluted on 40% EtOAc in pet ether to afford 2.2 g of brown liquid. LC-MS (ES+) [M+l]: 501.4 Step 4 : tert-Butyl 4-(4-((2-amino-2-methylpropyl)amino)-l,5-dimethyl-lH-pyrazol-3- yl)piperazine-l-carboxylate To solution of tert-Butyl 4-(4-((2-(((benzyloxy)carbonyl)amino)-2-methylpropyl)amino)-l,5- dimethyl-lH-pyrazol-3-yl)piperazine-l-carboxylate (2.0 g, 4.00 mmol) in EtOAc (60 ml) was added 10%> Pd-C ( 1.0 g) at RT and the reaction mixture was hydrogenated with H2 gas under balloon pressure stirring for 18 h. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The product was purified by trituration with npentane and diethyl ether to afford 0.7 g of brown solid. Step 5: tert-Butyl 4-(4-(3,3-dimethyl-5-oxopyrazolidin-l-yl)-l,5-dimethyl-lH-pyrazol- 3-yl)piperazine-l-carboxylate To a solution of tert-butyl 4-(4-((2-amino-2-methylpropyl)amino)-l,5-dimethyl-lH-pyrazol- 3-yl)piperazine-l-carboxylate (0.6 g, 1.63 mmol) in DCM (30 ml) was added Et N (0.46 ml, 3.27 mmol) at 0°C, followed by triphosgene (0.16 g, 0.54 mmol) and stirred at RT for 2 h. The reaction mixture was quenched with aq.NaHCC>3 and diluted with DCM, combined organic layer was washed with water and dried over sodium sulfate, and then concentrated under reduced pressure. The product was purified by washing with Ether/pentane to afford 0.2 g of off white solid. LC-MS (ES+) [M+l]: 393.3 Step 6: l-(l,5-Dimethyl-3-(piperazin-l-yl)-lH-pyrazol-4-yl)-4,4-dimethylimidazolidin- 2-one hydrochloride l-(l,5-Dimethyl-3-(piperazin-l-yl)-lH-pyrazol-4-yl)-4,4-dimethylimidazolidin-2-one hydrochloride was prepared as in intermediate example 1 step 5 using tert-butyl 4-(4-(3,3- dimethyl-5-oxopyrazolidin- 1-yl)- 1,5-dimethyl- lH-pyrazol-3-yl)piperazine- 1-carboxylate (0.5 g, 1.27 mmol), 1,4-dioxane-HCl (4 M, 30 ml) and dioxane (5 ml). The product was purified by trituration with n-pentane and diethyl ether to afford 390 mg of off-white solid. LC-MS (ES+) [M+l]: 293.1 Step 7: (5)-l-(3-(4-((2,3-Dihydrobenzo[b] [l,4]dioxin-2-yl)methyl)piperazin-l-yl)-l,5- dimethyl-lH-pyrazol-4-yl)-4,4-dimethylimidazolidin-2-one (S)- 1-(3-(4-((2,3-Dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- 1Hpyrazol- 4-yl)-4,4-dimethylimidazolidin-2-one was preapred according to the general procedure A2 using l-(l,5-dimethyl-3-(piperazin-l-yl)-lH-pyrazol-4-yl)-4,4-dimethylimidazolidin- 2-one, HC1 (137 mg, 0.417 mmol), (2i?)-2-(bromomethyl)-2,3-dihydro-l,4- benzodioxin (100 mg, 0.437 mmol), Na2C0 3 (69.4 mg, 0.655 mmol) and DMF (2 ml). The product was purified reversed phase flash chromatography using 0.1% HCOOH/ ACN as eluent to afford 36.6 mg of white solid. LC-MS (ES+) [M+l]: 441.3, 1H NMR (400 MHz, CDC13) d ppm 1.38 (s, 6H) 2.12 (s, 3H) 2.49 - 2.82 (m, 6H) 3.07 - 3.29 (m, 4H) 3.44 (s, 2H) 3.61 (s, 3H) 4.00 (dd, 1H) 4.25 - 4.39 (m, 2H) 4.48 (s, 1H) 6.72 - 7.00 (m, 4H). EXAMPLE 7: (5)-l-(3-(4-((2,3-Dihydrobenzo[b] [l,4]dioxin-2-yl)methyl)piperazin-lyl)- l,5-dimethyl-lH-pyrazol-4-yl)-3,4,4-trimethylimidazolidin-2-one Step 1: tert-Buty\ 4-(l,5-dimethyl-4-(3,4,4-trimethyl-2-oxoimidazolidin-l-yl)-lHpyrazol- 3-yl)piperazine-l-carboxylate To a solution of tert-butyl 4-(4-(4,4-dimethyl-2-oxoimidazolidin-l-yl)-l,5-dimethyl-lHpyrazol- 3-yl)piperazine-l -carboxylate (0.7 g, 1.78 mmol) in DMF (20 ml) was added 60% NaH (0.43 g, 17.85 mmol) at 0°C, and allowed stir at same temperature for 15 min and was added Mel (0. 11 ml, 1.78 mmol). The reaction mixture was gradually warmed to RT and stirred for 2 h. The reaction mixture was concentrated under reduced pressure. Evaporation residue was diluted with EtOAc and washed with water. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The product was purified by flash column using 2% MeOH in DCM as eluent to afford 0.3 g of viscous liquid. LC-MS (ES+) [M+l]: 407.3 Step 2 : l-(l,5-Dimethyl-3-(piperazin-l-yl)-lH-pyrazol-4-yl)-3,4,4-trimethylimidazolidin- 2-one hydrochloride 1-(1,5-Dimethyl-3-(piperazin- 1-yl)- 1H-pyrazol-4-yl)-3 ,4,4-trimethylimidazolidin-2-one hydrochloride was prepared as in intermediate example 1 step 5 using tert-butyl 4-(l,5- dimethyl-4-(3 ,4,4-trimethyl-2-oxoimidazolidin- 1-yl)- 1H-pyrazol-3 -yl)piperazine- 1- carboxylate (0.3 g, 0.74 mmol), 1,4-dioxane-HCl (4 M, 30 ml) and dioxane (5 ml). The product was purified by trituration with n-pentane and diethyl ether to afford 180 mg of offwhite solid. LC-MS (ES+) [M+l]: 307.3 Step 3 : (5)-l-(3-(4-((2,3-Dihydrobenzo[b] [l,4]dioxin-2-yl)methyl)piperazin-l-yl)-l,5- dimethyl-lH-pyrazol-4-yl)-3,4,4-trimethylimidazolidin-2-one (S)- 1-(3-(4-((2,3-Dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- 1Hpyrazol- 4-yl)-3,4,4-trimethylimidazolidin-2-one was prepared according to the general procedure A2 using l-(l,5-dimethyl-3-(piperazin-l-yl)-lH-pyrazol-4-yl)-3,4,4- trimethylimidazolidin-2-one, HC1 (150 mg, 0.437 mmol), (2R)- 2-(bromomethyl)-2,3- dihydro-l,4-benzodioxin (100 mg, 0.437 mmol), Na2C0 3 (69.4 mg, 0.655 mmol) and DMF (2 ml). The product was purified reversed phase flash chromatography using 0.1% HCOOH/ACN as eluent to afford 36.6 mg of white solid. LC-MS (ES+) [M+l]: 455.3, 1H NMR (400 MHz, CDC13) d ppm 1.3 1 (s, 6H) 2.05 - 2.1 1 (m, 3H) 2.53 - 2.75 (m, 6H) 2.77 (s, 3H) 3.15 (t, 4H) 3.34 (s, 2H) 3.61 (s, 3H) 4.00 (dd, 1H) 4.27 - 4.37 (m, 2H) 6.78 - 6.92 (m, 4H). EXAMPLE 8: (5)-4-(4-((2,3-Dihydrobenzo[b] [l,4]dioxin-2-yl)methyl)piperazin-l-yl)- 5-(methoxymethyl)thiazole Stepl : 2,4-Dibromothiazole-5-carbaldehyde Amixture of thiazolidine-2,4-dione (15.0 g, 128 mmol), POBr (183.6 g, 640 mmol) and DMF(10.8 ml,140.9 mmol) was heated to 75 °C for 1 h and then at 100 °C for 5 h. The reaction mixture was cooled to room temperature, diluted with CH2C 12 and washed with saturated NaHCC"3 solution, filtered and concentrated. Trituration of the evaporation residue with petroleum ether afforded 8.0 g of 2,4-dibromothiazole-5-carbaldehyde 8.0 g as black solid. Step 2 : (2,4-Dibromothiazol-5-yl)methanol To a solution of 2,4-dibromothiazole-5-carbaldehyde (8.0 g, 29.5 mmol) in methanol was added NaBH4 (1.16 g, 29.5 mmol) at 0 °C and the reaction was stirred for 16 at room temperature. The reaction mixture was concentrated, quenched with saturated NH4C 1 solution, basified with 0.IN NaOH solution and extracted with ethyl acetate. The combined organic layers were dried (Na2S0 4) , concentrated. Purification of the evaporation residue by column chromatography (30% EtOAc in petroleum ether) afforded 6.0 g of (2,4- dibromothiazol-5-yl)methanol as yellow solid. Step 3 : (4-Bromothiazol-5-yl)methanol To a solution of (2,4-dibromothiazol-5-yl)methanol (15.0 g, 54.9 mmol) in methanol (400 mL) was added 10% Pd/C (1.12 g) followed by Na2C0 3 (13.0 g) at RT. The reaction mixture was hydrogenated at 60 psi for 2 days at room temperature. The reaction mixture was filtered, washed with ethyl acetate and concentrated. Purification of the evaporation residue by column chromatography (30% EtOAc in petroleum ether) afforded 9.3 g of (4- bromothiazol-5-yl)methanol as yellow liquid. Step 4 : 4-Bromo-5-(methoxymethyl)thiazole Sodium hydride (1.67 g, 69.97 mmol, 60%>) was washed with dry n-pentane and dried under vacuum. Dry THF (300 mL) was added and the mixture was cooled in ice/water bath. A solution of (4-bromothiazol-5-yl)methanol (9.0 g, 46.7 mmol) in THF (100 mL) was added drop wise and the reaction mixture was stirred for 30 minutes. Methyl iodide (7.9 g, 56.0 mmol) was added at 0 °C and reaction mixture was stirred for 4h at room temperature. Ice cold water was added and the mixture was extracted with EtOAc. Combined organic layers were dried (Na2S0 4) and concentrated. The evaporation residue containing 4-bromo-5- (methoxymethyl)thiazole was directly taken for next step without further purification. Brown liquid. 8.0 g Step 5: 5-(Methoxymethyl)-4-(piperazin-l-yl)thiazole Amixture of 4-bromo-5-(methoxymethyl)thiazole (3.5 g, 16.8 mmol) and piperazine (1.74 g, 20.2 mmol) in toluene was degassed with argon for 20 min. To the mixture was added t- BuONa (3.23 g, 33.6 mmol) followed by Pd2(dba) 3 (0.77 g, 0.84 mmol), RuPhos (0.78 g, 1.68 mmol) at room temperature and the reaction mixture was heated to reflux for 12h The reaction mixture was filtered, and concentrated. Purification of the evaporation residue by column chromatography (20%MeOH/CH 2Cl2) afforded 0.4 g of 5-(methoxymethyl)-4- (piperazin-l-yl)thiazole as brown solid m/z [M+l]: 214.1. Step 6: (5)-4-(4-((2,3-Dihydrobenzo[b] [l,4]-dioxin-2-yl)methyl)piperazin-l-yl)-5- (methoxymethyl)thiazole (5)-4-(4-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)-5- (methoxymethyl)thiazole was prepared according to the general procedure Al using 5- (methoxymethyl)-4-(piperazin-l-yl)thiazole (0.10 g, 0.47 mmol), K2C0 3 (0.097 g, 0.70 mmol), (2R)- 2-(bromomethyl)-2,3-dihydro-l,4-benzodioxin (0.107 g, 0.47 mmol) and acetonitrile ( 1.25 ml). After the general procedure work-up, the evaporation residue was taken in mixture of EtOAc and water. Organic layer was separated and the water layer was extracted with EtOAc. Combined organic phases were washed with water and brine, dried and concentrated. The evaporation residue was purified by flash chromatography using 20- 80% EtOAc in heptane as eluent to afford 0.080 g of (5)-4-(4-((2,3-dihydrobenzo[b][l,4]- dioxin-2-yl)methyl)piperazin-l-yl)-5-(methoxymethyl)thiazole as semi-solid. 1H NMR (400 MHz, CDC13) d ppm 2.62 - 2.70 (3 H, m), 2.71 - 2.79 (3 H, m), 3.22 - 3.29 (4 H, m), 3.39 (3 H, s), 4.03 ( 1 H, dd), 4.31 - 4.38 (2 H, m), 4.55 (2 H, s), 6.81 - 6.91 (4 H, m), 8.55 ( 1 H, s). EXAMPLE 9: (5)-l-(3-(4-((2,3-Dihydrobenzo[b] [l,4]dioxin-2-yl)methyl)piperazin-lyl)- 1,5-dimethyl-lH-pyrazol-4-yl)imidazolidin-2-one Step 1: tert-Butyl 4-(l,5-dimethyl-4-nitro-lH-pyrazol-3-yl)piperazine-l-carboxylate To a suspension of l,5-dimethyl-3,4-dinitro-lH-pyrazole (0.30 g, 1.6 mmol) in isopropanol (12 ml) was added tert-butyl 1-piperazinecarboxylate (0.85 g, 4.8 mmol) and the mixture was heated in microwave reactor at 140 °C for 16 hours. Solvents were evaporated. Purification of evaporation residue by flash chromatography (20-50 % EtOAc in heptane) afforded 0.29 g of tert-butyl 4-(l,5-dimethyl-4-nitro-lH-pyrazol-3-yl)piperazine-lcarboxylate as an yellow oil. LC-MS (ES+) [M+l]: 326.4. Step 2 : tert-Butyl 4-(4-amino-l,5-dimethyl-lH-pyrazol-3-yl)piperazine-l-carboxylate To a solution of tert-butyl 4-(l,5-dimethyl-4-nitro-lH-pyrazol-3-yl)piperazine-l-carboxylate ( 1.26 g, 3.87 mmol) in a mixture of THF (14 ml), MeOH (16 ml) and water (8 ml) was added NH4C 1 (2.07 g, 38.7 mmol) and the mixture was cooled with an ice bath. Zinc powder (2.53 g, 38.7 mmol) was added and the mixture was stirred at room temperature. After 15 minutes the reaction mixture was diluted with EtOAc (50 ml) and filtered. Precipitate was washed with EtOAc and the filtrate was washed with brine, dried (Na2S0 4) and concentrated. The evaporation residue was taken in dichloromethane, filtered and the solution was concentrated. Redissolution into dichloromethane - heptane and successive evaporation of solvents afforded 1.04 g tert-butyl 4-(4-amino-l,5-dimethyl-lH-pyrazol-3- yl)piperazine-l-carboxylate as grey solid. LC-MS (ES+) [M+l]: 296.6. Step 3 : tert- ty 4-(l,5-dimethyl-4-(2-oxoimidazolidin-l-yl)-lH-pyrazol-3- yl)piperazine-l-carboxylate To a solution of tert-butyl 4-(4-amino-l,5-dimethyl-lH-pyrazol-3-yl)piperazine-lcarboxylate (0.21 g, 0.71 mmol) in THF (7 ml) was added 2-chloroethyl isocyanate (0.073 ml, 0.85 mol). After 3h potassium t rt-butoxide (0.16 g, 1.42 mmol) was added and the resulting mixture was stirred at room temperature for 3.5 hours. Saturated solution of NH4C 1 (5 ml) was added to the reaction mixture and THF was evaporated. The residue was partitioned between dichloromethane (10 ml) and water (10 ml) and the water layer was extracted with dichloromethane. Combined organic layers were washed with water, dried (Na2S0 4) and concentrated to afford 0.25 g of tert-butyl 4-(l,5-dimethyl-4-(2- oxoimidazolidin-l-yl)-lH-pyrazol-3-yl)piperazine-l-carboxylate as an oil. LC-MS (ES+) [M+l]: 365.3. Step 4 : l-(l,5-Dimethyl-3-(piperazin-l-yl)-lH-pyrazol-4-yl)imidazolidin-2-one tert-Butyl 4-( 1,5-dimethyl-4-(2-oxoimidazolidin- 1-yl)- 1H-pyrazol-3 -yl)piperazine- 1- carboxylate (0.24 g, 0.67 mmol) was mixed with trifluoroacetic acid (3.5 ml) and the resulting solution was stirred at room temperature for 3 hours. Evaporation of trifluoroacetic acid afforded 0.44 g of the bis-trifluoroacetic acid salt of l-(l,5-dimethyl-3-(piperazin-l-yl)- lH-pyrazol-4-yl)imidazolidin-2-one as an oil. LC-MS (ES+) [M+l]: 265.5. Step 5: (5)-l-(3-(4-((2,3-dihydrobenzo[b] [l,4]dioxin-2-yl)methyl)piperazin-l-yl)-l,5- dimethyl-lH-pyrazol-4-yl)imidazolidin-2-one (S)- 1-(3-(4-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- 1Hpyrazol- 4-yl)imidazolidin-2-one was prepared according to the general procedure Al using bis-trifluoroacetic acid salt of l-(l,5-dimethyl-3-(piperazin-l-yl)-lH-pyrazol-4- yl)imidazolidin-2-one 0.10 g, 0.20 mmol), di-isopropylethylamine (0.035 ml, 0.20 mmol), K2C0 3 (0.056 g, 0.41 mmol), (2R)- 2-(bromomethyl)-2,3-dihydro-l,4-benzodioxin (0.047 g, 0.20 mmol) and acetonitrile ( 1 ml). The product was purified by flash chromatography (0- 10% MeOH in dichloromethane) to afford 0.060 g of (S)- 1-(3-(4-((2,3- dihydrobenzo[b] [1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- lH-pyrazol-4- yl)imidazolidin-2-one as a yellowish solid. 1H NMR (400 MHz, DMSO-d 6) d ppm 1.99 (3 H, s), 2.53 - 2.64 (5 H, m), 3.96 - 3.06 (4 H, m), 3.34 - 3.39 (2 H, m), 3.48 - 3.56 (2 H, m), 3.54 (3H, obs.s), 3.96 (1H, dd), 4.27 - 4.32 ( 1 H, m), 4.36 ( 1 H, br s), 6.44 ( 1 H, s), 6.78 - 6.89 (4 H, m). EXAMPLE 10: (5)-l-((2,3-Dihydrobenzo[b] [l,4]dioxin-2-yl)methyl)-4-(l-(pyridin-2- yl)-lH-pyrazol-5-yl)piperazine Step 1: l-(4-Benzylpiperazin-l-yl)-3,3-diethoxypropan-l-one To a suspension of sodium 3,3-diethoxypropanoate (6.41 g, 34.8 mmol, prepared as described in EP1426366 Al) in dimethylformamide (70 ml) was added l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (8.0 g, 41.8 mmol), 1- hydroxybenzoltriazole (6.35 g, 47.0 mmol) and 1-benzylpiperazine (4.0 ml, 34.8 mmol). After 3 days DMF was evaporated in vacuo and water was (50 ml) was added to the residue. Mixture was extracted with EtOAc. The combined organic layers were washed with saturated NaHCC"3 and brine, dried (Na2S04) and concentrated. Purification of the orange oily evaporation residue by flash chromatography (10-100% EtOAc-heptane) afforded 4.71 g of l-(4-benzylpiperazin-l-yl)-3,3-diethoxypropan-l-one as yellow oil. LC-MS (ES+) [M+l]: 321.6. Step 2 : l-Benzyl-4-(l-(pyridin-2-yl)-lH-pyrazol-5-yl)piperazine To a solution of l-(4-benzylpiperazin-l-yl)-3,3-diethoxypropan-l-one (4.7 g, 14.7 mmol) in chloroform (40 ml) at 0 °C was added a mixture of trifluoroacetic acid (14 ml) and water (14 ml) and the mixture was stirred vigorously. After 24 hours chloroform (40 ml) was added and pH of the solution was adjusted to 6-7 by adding 5M NaOH. Phases were separated and water phase was extracted with dichloromethane (50 ml). Combined organic phases were dried (Na2S0 4) and concentrated to dryness- The resulting yellow oily evaporation residue was dissolved in EtOH (70 ml) and to the solution were added methanesulfonic acid (0.095 ml, 1.47 mmol) and 2-hydrazinopyridine (1.60 g, 14.7 mmol). After 17 hours pyridine (1.4 ml) was added and the mixture was evaporated to dryness. The evaporation residue was taken into pyridine (70 ml) and phosphorus oxychloride (2.70 ml, 29.0 mmol) was added. After 19 hours the reaction mixture was concentrated to dryness. To the resulting brown glue was added EtOAc (60 ml) and water (25 ml) and after stirring for a while the phases were separated. The water layer was made clearly basic by addition of 5M NaOH and solution was extracted with EtOAc. Organic phases were combined, washed with brine, dried (Na2S0 4) and solvents were evaporated. Purification of the evaporation residue by flash chromatography (MeOH-dichloromethane) afforded 0.23 g of l-benzyl-4-(l-(pyridin-2- yl)-lH-pyrazol-5-yl)piperazine as brown oil. LC-MS (ES+) [M+l]: 320.2. Step 3 : l-(l-(Pyridin-2-yl)-lH-pyrazol-5-yl)piperazine A solution of l-benzyl-4-(l-(pyridin-2-yl)-lH-pyrazol-5-yl)piperazine (0.23 g, 0.72 mmol) in acetic acid (14 ml) was hydrogenated in flow reactor (ThalesNano H-Cube, Pd/C-column, flow rate 1 ml/min, 80 °C, 80 bar H2-pressure) repeating the run twice with fresh Pd/Ccolumn. Solvents were evaporated and the resulting yellow oil was taken into mixture of NaHCOs and dichloromethane. Phases were separated and the aqueous phase was extracted first with dichloromethane and then with 20% isopropanol-EtO Ac-mixture. The combined organic phases were dried (Na2S0 4) and concentrated. Purification of the evaporation residue by flash chromatography (1-15% MeOH in dichloromethane + 2% triethylamine) afforded 0.049 g of l-(l-(pyridin-2-yl)-lH-pyrazol-5-yl)piperazine as brown oil. LC-MS (ES+) [M+l]: 230.1. Step 4 : (5)-l-((2,3-dihydrobenzo[b] [l,4]dioxin-2-yl)methyl)-4-(l-(pyridin-2-yl)-lHpyrazol- 5-yl)piperazine (S)- 1-((2,3-Dihydrobenzo[b] [1,4]dioxin-2-yl)methyl)-4-( 1-(pyridin-2-yl)- 1H-pyrazol-5- yl)piperazine was prepared according to the general procedure Al using l-(l-(pyridin-2-yl)- lH-pyrazol-5-yl)piperazine (0.047 g, 0.21 mmol), di-isopropylethylamine (0.036 ml, 0.21 mmol), K2C0 3 (0.028 g, 0.21 mmol), (2R)- 2-(bromomethyl)-2,3-dihydro-l,4-benzodioxin (0.047 g, 0.21 mmol) and acetonitrile (0.9 ml). The product was purified by flash chromatography (0-10% MeOH in dichloromethane + 2% triethylamine) to afford 0.006 g of (S)- 1-((2,3-dihydrobenzo[b] [1,4]dioxin-2-yl)methyl)-4-( 1-(pyridin-2-yl)- 1H-pyrazol-5- yl)piperazine as a yellow oil 1H NMR (400 MHz, CDC13) d ppm 2.60 - 2.67 (3 H, m), 2.67 - 2.77 (3 H, m), 2.95 - 2.96 - 3.06 (4 H, m), 4.00 ( 1 H, dd), 4.27 - 4.34 (2 H, m), 5.88 ( 1 H, d), 6.80 - 6.90 (4 H, m), 7.20 -7.24 ( 1 H, m), 7.57 ( 1 H, d), 7.77 - 7.87 (2 H, m), 8.55 ( 1 H, ddd). EXAMPLE 11: (S)-l-((2,3-Dihydrobenzo[b][l,4]dioxin-2-yl)methyl)-4-(4- (methoxymethyl)-1,5-dimethyl-lH-pyrazol-3-yl)piperazine Step 1: 4-Benzylpiperazine-l-carbothioyl hydrochloride To a solution of thiophosgene (4.4 ml, 57 mmol) in THF (40 ml) at 0 °C was added a solution of 1-benzylpiperazine (9.7 ml, 57 mmol) in THF (35 ml) over 35 minutes, keeping the reaction temperature below 5 °C during addition. The reaction mixture was stirred at 0 °C. After 1.5 hours the reaction mixture was filtered and the precipitate was washed with cold diethyl ether (2 x 10 ml). Drying the precipitate afforded 17 g of crude 4- benzylpiperazine-l-carbothioyl hydrochloride as yellowish solid. Step 2 : Ethyl 5-(4-benzylpiperazin-l-yl)-3-methyl-lH-pyrazole-4-carboxylate To a solution of crude 4-benzylpiperazine-l-carbothioyl hydrochloride (2.0 g, 6.9 mmol) in ethanol (8 ml) was added triethylamine (0.96 ml, 6.9 mmol) and solution was cooled to 0 °C. Hydrazine monohydrate (0.67 ml, 13.7 mmol) was added in a manner that kept the reaction temperature below 4 °C. The reaction mixture was let to warm up spontaneously on an ice bath. After 24 hours HCl-ethanol solution, prepared by addition of thionyl chloride (2.5 ml, 34.3 mmol) to ethanol (10 ml) at 0 °C, was added to the reaction mixture while cooling the reaction vessel with an ice bath. After 10 minutes ethyl-2-chloroacetoacetate (1.9 ml, 13.7 mmol) was added and the reaction mixture was stirred at room temperature for 3 days. Solvents were evaporated and 1M HC1 (20 ml) was added along with some water to dissolve other material than elemental sulphur. The sulphuric precipitate was washed with water and combined water layers were washed with EtOAc (70 ml). The pH of the water phase was adjusted to 10 using saturated NaHC0 3 and 5M NaOH solution. The basic water solution was extracted with EtOAc (3x). Combined organic phases were washed with brine and solvents were evaporated. The oily evaporation residue was dissolved in dichloromethaneheptane mixture. Evaporation of the solvents afforded 1.75 g of crude ethyl 5-(4- benzylpiperazin-l-yl)-3 -methyl- lH-pyrazole-4-carboxylate as a brown solid. LC-MS (ES+) [M+l]: 330.3. Step 3 : Ethyl 3-(4-benzylpiperazin-l-yl)-l,5-dimethyl-lH-pyrazole-4-carboxylate To a solution of ethyl 5-(4-benzylpiperazin-l-yl)-3 -methyl- lH-pyrazole-4-carboxylate (1.3 g, 4.0 mmol) in DMF (13 ml) at 0 °C was added sodium hydride (0.22 g, 5.54 mmol, 60 m-% dispersion in mineral oil). After 20 minutes, iodomethane (0.30 ml, 4.8 mmol) was added and the cooling bath was removed. After 4 hours water (40 ml) was added and the mixture was extracted with EtOAc (3 x 30 ml). Combined organic phases were washed with brine, dried (Na2S0 4) and concentrated to dryness. Purification of the oily evaporation residue by flash chromatography (MeOH-dichloromethane) afforded 0.4 g of ethyl 3-(4-benzylpiperazin-lyl)- l,5-dimethyl-lH-pyrazole-4-carboxylate as yellowish solid. LC-MS (ES+) [M+l]: 343.8. Step 4: (3-(4-Benzylpiperazin- 1-yl)-1,5-dimethyl- lH-pyrazol-4-yl)methanol To a solution of ethyl 3-(4-benzylpiperazin-l-yl)-l,5-dimethyl-lH-pyrazole-4-carboxylate (0.4 g, 1.17 mmol) in THF (4 ml) at 0 °C was added lithium aluminum hydride (0.044 g, 1.17 mmol) and the reaction mixture was stirred at 0 °C. After 2 hours the mixture was brought to room temperature and after further 5 hours lithium aluminum hydride (0.022 g, 0.59 mmol) was added. Mixture was stirred at room temperature overnight. To the reaction mixture was added water (70 mΐ), 15% NaOH (70 mΐ) and water (0.2 ml). After l h precipitate was filtered and washed with EtOAc. The filtrate was washed with water and brine and dried (Na2S0 4) . Evaporation of the solvents afforded 0.26 g of (3-(4- benzylpiperazin-l-yl)-l,5-dimethyl-lH-pyrazol-4-yl)methanol as off white solid which was used without further purification. LC-MS (ES+) [M+l]: 301.3. Step 5: l-Benzyl-4-(4-(methoxymethyl)- 1,5-dimethyl- lH-pyrazol-3-yl)piperazine To a solution of (3-(4-benzylpiperazin-l-yl)-l,5-dimethyl-lH-pyrazol-4-yl)methanol (0.26 g, 0.87 mmol) in DMF (3 ml) at 0 °C was added sodium hydride (0.045 g, 1.13 mmol, 60 m-% dispersion in mineral oil). After 20 minutes, iodomethane (0.054 ml, 0.87 mmol) was added. The cooling bath was removed after 1.5 hours. After 6 hours sodium hydride (0.030 g, 0.75 mmol) and iodomethane (0.010 ml, 0.16 mmol) were added and the reaction mixture was stirred at room temperature overnight. Saturated solution of NH4C 1was added and mixture was extracted with EtOAc. Combined organic phases were washed with brine and dried (Na2S0 4) . Evaporation of the solvents afforded 0.22 g of oil containing a mixture of starting material and methylated product. To the crude product in DMF (2.4 ml) at 0 °C was added sodium hydride (0.029 g, 0.73 mmol). After 10 minutes, iodomethane (0.046 ml, 0.73 mmol) was added and the mixture was stirred at 0 °C for 1 h and then at room temperature for 2 hours. Water was added and the precipitate was filtered, washed (water) and dried in vacuum oven (30°C) Yield 0.088 g of l-benzyl-4-(4-(methoxymethyl)-l,5-dimethyl-lH-pyrazol-3-yl)piperazine as white solid. LC-MS (ES+) [M+l]: 315.2. Step 6: l-(4-(Methoxym ethyl)-1,5-dimethyl-lH-pyrazol-3-yl)piperazine To a solution of l-benzyl-4-(4-(methoxymethyl)-l,5-dimethyl-lH-pyrazol-3-yl)piperazine (0.087 g, 0.28 mmol) and formic acid (0.021 ml, 0.55 mmol) in methanol (1.4 ml) was added ammonium formate (0.174 g, 2.77 mmol) and 10% Pd/C (0.059 g, 0.055 mmol). The mixture was heated in reflux. After 2.5 hours the reaction mixture was cooled and filtered through a pad of celite. The filter cake was washed with a mixture of MeOH and formic acid. Filtrate was concentrated to dryness and the evaporation residue was taken into a mixture of dichloromethane and sat. NaHCC"3. Phases were separated and aqueous phase was extracted with dichloromethane. Combined organic phases were washed with brine and dried (Na2S0 4) . Evaporation of the solvents afforded 0.018 g of l-(4-(methoxymethyl)-l,5- dimethyl-lH-pyrazol-3-yl)piperazine as cloudy oil that was used as such in the next step. LC-MS (ES+) [M+l]: 224.9. Step 7: (5)-l-((2,3-Dihydrobenzo[b] [l,4]dioxin-2-yl)methyl)-4-(4-(methoxymethyl)-l,5- dimethyl-lH-pyrazol-3-yl)piperazine (5)-l-((2,3-Dihydrobenzo[b][l,4]dioxin-2-yl)methyl)-4-(4-(methoxymethyl)-l,5-dimethyllH- pyrazol-3-yl)piperazine was prepared according to the general procedure Al using l-(4- (methoxymethyl)-l,5-dimethyl-lH-pyrazol-3-yl)piperazine (0.017 g, 0.076 mmol), diisopropylethylamine (0.016 ml, 0.091 mmol), K2C0 3 (0.016 g, 0.1 14 mmol), (2R)- 2- (bromomethyl)-2,3-dihydro-l,4-benzodioxin (0.017 g, 0.076 mmol) and acetonitrile (0.4 ml). The product was purified by reverse phase flash chromatography (0.1% NH4OH-acetonitrile) to afford 0.0047 g of (5)-l-((2,3-dihydrobenzo[b][l,4]dioxin-2-yl)methyl)-4-(4- (methoxymethyl)-l,5-dimethyl-lH-pyrazol-3-yl)piperazine as brown oil. 1H NMR (400 MHz, CDC13) d ppm 2.19 (3 H, s), 2.60 - 2.68 (3 H, m), 2.68 - 2.79 (3 H, m), 3.14- 3.25 (4 H, m), 3.32 (3 H, s), 3.64 (3 H, s), 4.01 ( 1 H, dd), 4.19 (2 H, s), 4.29 - 4.38 (2 H, m), 6.79 - 6.92 (4 H, m). EXAMPLE 12: (5)-Ethyl 3-(4-((2,3-dihydrobenzo[b][l,4]dioxin-2-yl)methyl)piperazin- 1-yl)-1,5-dimethyl- lH-pyrazole-4-carboxylate Step 1: Ethyl l,5-dimethyl-3-(piperazin-l-yl)-lH-pyrazole-4-carboxylate To a solution of ethyl 3-(4-benzylpiperazin-l-yl)-l,5-dimethyl-lH-pyrazole-4-carboxylate (0.40 g, 1.17 mmol) (obtained as described in Example 1 1 Step 1-2) and formic acid (0.088 ml, 2.33 mmol) in MeOH (6 ml) was added ammonium formate (0.74 g, 11.7 mmol) and 10% Pd/C (0.250 g, 0.23 mmol). The reaction mixture was stirred at 45 °C. After 2.5 hours the reaction mixture was cooled and filtered through a pad of celite. The filter cake was washed with a mixture of MeOH and formic acid. Filtrate was concentrated to dryness and the evaporation residue was taken into mixture of dichloromethane and sat. NaHCC"3. Phases were separated and aqueous phase was extracted with dichloromethane and EtOAc. Combined organic phases were washed with brine and dried (Na2S0 4) . Evaporation of the solvents afforded 0.22 g of ethyl l,5-dimethyl-3-(piperazin-l-yl)-lH-pyrazole-4-carboxylate as brown solidifying oil that was used as such in the next step. LC-MS (ES+) [M+l]: 253.1. Step 2 : (5)-Ethyl 3-(4-((2,3-dihydrobenzo[b][l,4]dioxin-2-yl)methyl)piperazin-l-yl)- 1,5-dimethyl- lH-pyrazole-4-carboxylate (S)-Ethyl 3-(4-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,5-dimethyllH- pyrazole-4-carboxylate was prepared according to the general procedure Al using ethyl l,5-dimethyl-3-(piperazin-l-yl)-lH-pyrazole-4-carboxylate (0.22 g, 0.87 mmol), diisopropylethylamine (0.18 ml, 1.05 mmol), K2C0 3 (0.180 g, 1.31 mmol), (2R)- 2- (bromomethyl)-2,3-dihydro-l,4-benzodioxin (0.20 g, 0.87 mmol) and acetonitrile (2.9 ml). The product was purified by reverse phase flash chromatography (0.1% HCOOHacetonitrile) to afford 0.1 1 g of ( Pd/C (0.151 g, 0.142 mmol) was added followed by formic acid (0.534 ml, 14.16 mmol). Mixture was heated to 50 °C under nitrogen atmosphere for 1 h, then heated to 70 °C for 2 h. Another batch of 10% Pd/C (0.151 g, 0.142 mmol) followed by ammonium formate (0.893 g, 14.16 mmol) were added. Then mixture was heated at 70 °C under nitrogen for 3 h. Reaction mixture was cooled to RT and filtered through celite followed by EtOH washings. Filtrate was basified by addition of 50%> NaOH until pH is 10- 11 and then water (10 mL) was added to redissolved formed solids. Mixture was stirred for 1 h and most of the solvents were evaporated. Residual aqueous phase was extracted with 20% IPA / EtOAc (3 x 20 mL). Combined organic extracts were dried with anhydrous Na2S0 4 and evaporated to dry to give 0.266 g of 1-(3-methyl- l-(pyridin-2-yl)- lH-pyrazo 1-5- yl)piperazine as solids. Product was used as such in the next step. LC-MS (ES+) [M+l]: 244.5. Step 4 : (5)-l-((2,3-Dihydrobenzo[b] [l,4]dioxin-2-yl)methyl)-4-(3-methyl-l-(pyridin-2- yl)-lH-pyrazol-5-yl)piperazine A flask was charged with 1-(3-methyl- l-(pyridin-2-yl)-lH-pyrazo 1-5 -yl)piperazine (0.250 g, 1.03 mmol), (i?)-2-(bromomethyl)-2,3-dihydrobenzo[b][l,4]dioxine (0.259 g, 1.13 mmol), Na2C0 3 (0.163 g, 1.54 mmol) and DMF (5 mL). Mixture was heated to 110-120 °C for 2 h. Reaction was cooled to RT, then EtOAc (20 mL) and water (20 mL) were added. Aqueous phase was extracted with EtOAc (20 mL). Combined organic phases were washed with brine (20 mL), dried with anhydrous Na2S0 4 and evaporated to dry. Crude product was purified with reverse phase chromatography (C18) using 10-100% MeCN / 0.5% HC0 2H solution followed by another purification (CI 8) with 10-100% MeCN / 0.1% NH4OH solution to give 0.194 g of (5)-l-((2,3-dihydrobenzo[b][l,4]dioxin-2-yl)methyl)-4-(3-methyl-l-(pyridin- 2-yl)-lH-pyrazol-5-yl)piperazine as white powder. 1H NMR (400 MHz, CDC13) d ppm 2.29 (3H, s), 2.56-2.66 (3H, m), 2.66-2.79 (3H, m), 2.91-3.05 (4H, m), 4.00 (1H , dd), 4.23-4.36 (2H, m), 5.70 (1H, s), 6.77-6.93 (4H, m), 7.17 (1H, ddd), 7.76 (1H, ddd), 7.85 (1H, dt), 8.54 (1H, ddd). EXAMPLE 39: (5)-l-((2,3-Dihydrobenzo[b] [l,4]dioxin-2-yl)methyl)-4-(l-(6- methoxypyridin-2-yl)-3-methyl-lH-pyrazol-5-yl)piperazine Step 1: l-(6-Methoxypyridin-2-yl)-3-methyl-lH-pyrazol-5-amine A flask was charged with 2-hydrazinyl-6-methoxypyridine (1.1 g, 7.90 mmol, prepared according to Biorg. Med. Chem. Lett. 2011, 21, 2316-2319), 3-aminocrotononitrile (0.649 g, 7.90 mmol) and MeOH (14 mL). To this was added AcOH (2 mL) and reaction was heated to reflux for 3 h. Mixture was cooled to RT and evaporated to near dry. Residue was partitioned between sat. NaHC0 3 solution (20 mL) and EtOAc (20 mL). Aqueous phase was extracted with EtOAc (10 mL). Combined organic phases were washed with brine (20 mL), dried with anhydrous Na2S0 4 end evaporated to dry to give 1.525 g of l-(6-methoxypyridin- 2-yl)-3-methyl- IH-pyrazo 1-5-amine as solids. Product was used as such in the next step. LCMS (ES+) [M+l]: 205.5. CLAIMS 1. A com ound of formula I, wherein A is a five membered unsaturated heterocyclic ring containing 1, 2 or 3 ring heteroatom(s) each independently selected from N, O and S, wherein said heterocyclic ring is unsubstituted, or said heterocyclic ring is substituted with 1 substituent Ri, or said heterocyclic ring is substituted with 2 substituents Ri and R2, or said heterocyclic ring is substituted with 3 substituents Ri, R2, and R3, or said heterocyclic ring is substituted with 4 substituents Ri, R2, R3 and R4 Ri is (Ci-C )alkyl, (Ci-C )alkoxy, hydroxy(Ci-C )alkyl, (Ci-C )alkoxy(Ci-C )alkyl, (C C6)alkoxy-(C=0)-, CN, (Ci-C6)alkyl-(C=0)-, R R -, heterocyclyl, heterocyclyl-N-, or phenyl-N-, wherein said heterocyclyl or phenyl is optionally substituted with 1,2, 3, or 4 substituent(s) each independently being (Ci-C6)alkyl, (Ci- C6)alkoxy, oxo, or phenyl(Ci-C 6)alkoxy; R2 is (Ci-C6)alkyl, (Ci-C6)alkoxy, or (C1-C6)alkoxy(C1-C6)alkyl; R3 is (Ci-C6)alkyl, (Ci-C6)alkoxy, or (C1-C6)alkoxy(C1-C6)alkyl; R4 is (Ci-C6)alkyl; R is H, or (Ci-C6)alkyl; and R is H, or (Ci-C6)alkyl; or Ri and R2 form, together with the ring atoms to which they are attached, a condensed 6 membered unsaturated heterocyclic ring, containing 1 or 2 heteroatom(s) being N; or a pharmaceutically acceptable salt or ester thereof; with the proviso that A is not l,2,3-oxadiazol-3-ium-3-yl. 2. The compound according to claim 1, wherein the compound is a compound of formula 3. The compound according to any one of claims 1 or 2 , wherein ring A is any one of the following groups (2) (3) (4) (5) (6) (7) (8) (9) (10) (17) ( 18) (19) (20) (21) (22) wherein Z is N, O or S; and atom marked with * is bonded to the parent molecular moiety. 4. The compound according to any one of claims 1 to 3, wherein Ri is (Ci-C6)alkyl, (Ci- C )alkoxy, hydroxy(Ci-C )alkyl, (C1-C6)alkoxy(C1-C6)alkyl, (C C6)alkoxy-(C=0)-, CN, (Ci-C6)alkyl-(C=0)-, R R -, phenyl-N-, or any one of the following groups wherein atom marked with * is bonded to the parent molecular moiety; group ( 1') to ( 11') is optionally substituted with 1,2, 3, or 4 substituent(s) each independently being (Ci-C6)alkyl, ( -C6)alkoxy, oxo, or phenyl(d-C 6)alkoxy. 5. The compound according to any one of claims 1 to 4, wherein ring A is any one of the groups (1), (2), (3), (4), (5), (6), (7), (8), (9), or (10) wherein group (1), (2), (3), (4), (5), (6), (7), (8), (9), or (10) is unsubstituted, or group (1), (2), (3), (4), (5), (6), (7), (8), (9), or (10) is substituted with 1 substituent R or group (1), (2), (3), (4), (5), (6), (7), (8), (9), or (10) is substituted with 2 substituents Ri and R2, or group (1), (2), (3), (4), (5), (6), (7), (8), (9), or (10) is substituted with 3 substituents Ri, R2, and R3; Ri is hydroxy(Ci-C )alkyl, (C1-C6)alkoxy(C1-C6)alkyl, (C C6)alkoxy-(C=0)-, CN, (C C6)alkyl-(C=0)-, or any one of the groups ( ), (2'), (3'), (4'), (5'), (6'), (7'), (8'), (9'), or (10'), wherein group (1'), (2'), (3'), (4'), (5'), (6'), (7'), (8'), (9'), or (10'), is optionally substituted with 1,2, 3, or 4 substituent(s) each independently being (Ci-C6)alkyl, (Ci-C6)alkoxy, oxo, or phenyl(Ci-C6)alkoxy; R2 is (Ci-C )alkyl; R3 is (Ci-C6)alkyl; R is H, or (Ci-C6)alkyl; and R is H, or (Ci-C6)alkyl; or Ri and R2 form, together with the ring atoms to which they are attached, a condensed 6 membered unsaturated heterocyclic ring, containing 1heteroatom being N. 6. The compound according to any one of claims 1to 5, wherein ring A is any one of the groups (1), (2), (4), (7), (8), (9), or (10), wherein group (1), (2), (4), (7), (8), (9), or (10) is substituted with 1 substituent Ri, or group (1), (2), (4), (7), (8), (9), or (10) is substituted with 2 substituents Ri and R2, or group (1), (2), (4), (7), (8), (9), or (10) is substituted with 3 substituents Ri, R2, and R3; Ri is (Ci-C6)alkoxy(Ci-C 6)alkyl, R R6N-(C=0)-, or any one of the groups (2'), (4'), (5'), or (9'), wherein group (2'), (4'), (5'), or (9') is optionally substituted with 1,2, 3, or 4 substituent(s) each independently being ( -C6)alkyl or oxo; R2 is (Ci-C6)alkyl; R3 is (Ci-C6)alkyl; R is (Ci-C6)alkyl; and R is (Ci-C6)alkyl. 7. The compound according to any one of claims 1 to 4, wherein ring A is any one of the following groups Ri is hydroxy(Ci-C )alkyl, (C1-C6)alkoxy(C1-C6)alkyl, (C C6)alkoxy-(C=0)-, CN, (C C6)alkyl-(C=0)-, or any one of the groups ( ), (2'), (3'), (4'), (5'), (6'), (7'), (8'), (9'), or ( I O'), wherein group (1'), (2'), (3'), (4'), (5'), (6'), (7'), (8'), (9'), or ( I O'), is optionally substituted with 1,2, 3, or 4 substituent(s) each independently being (Ci-C 6)alkyl, (Ci-C 6)alkoxy, oxo, or phenyl(Ci-C 6)alkoxy; R2 is (Ci-C )alkyl; R3 is (Ci-C 6)alkyl; R is H, or (Ci-C 6)alkyl; and R is H, or (Ci-C 6)alkyl; or Ri and R2 form, together with the ring atoms to which they are attached, a condensed 6 membered unsaturated heterocyclic ring, containing 1 heteroatom being N . 8. The com ound according to claim 7, wherein ring A is any one of the following groups Ri is R R6N-(C=0)- or any one of groups (2'), (4'), (5'), or (9'), wherein group (2'), (4'), (5'), or (9') is optionally substituted with 1,2, or 3 substituent(s) each independently being (Ci-C 3)alkyl or oxo; R2 is (Ci-C3)alkyl; R3 is (Ci-C3)alkyl; R is (Ci-C3)alkyl; and is (Ci-C3)alkyl. 9. The compound according to claim 1, wherein the compound is (S)-l-(3-(4-((2,3- dihydrobenzo[b] [1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- 1H-pyrazol-4-yl)-3 ,3- dimethylpyrrolidine-2,5-dione, (5)-2-(3-(4-((2,3-dihydrobenzo[b][l,4]dioxin-2- yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- lH-pyrazol-4-yl)isoindoline- 1,3-dione, (¾)-5-(4- ((2,3-dihydrobenzo[b][l,4]dioxin-2-yl)methyl)piperazin-l-yl)-2-methyloxazole-4- carbonitrile, (S)- 1-(3-(4-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,5- dimethyl- lH-pyrazol-4-yl)azetidin-2-one, (¾)-3-(3-(4-((2,3-dihydrobenzo[b][l,4]dioxin-2- yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- lH-pyrazol-4-yl)oxazolidin-2-one, (S)- 1-(3-(4-((2,3 dihydrobenzo [b] [1,4] dioxin-2-yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- 1H-pyrazol-4-yl)-4,4- dimethylimidazolidin-2-one, (S)- 1-(3-(4-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2- yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- 1H-pyrazol-4-yl)-3 ,4,4-trimethylimidazolidin-2-one, (5)-4-(4-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)-5- (methoxymethyl)thiazole, (S)- 1-(3-(4-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2- yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- lH-pyrazol-4-yl)imidazolidin-2-one, (S)- 1-((2,3- dihydrobenzo[b] [1,4] dioxin-2-yl)methyl)-4-( 1-(pyridin-2-yl)- 1H-pyrazol-5 -yl)piperazine, (S)- 1-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)-4-(4-(methoxymethyl)- 1,5-dimethyllH- pyrazol-3-yl)piperazine, (5)-ethyl 3-(4-((2,3-dihydrobenzo[b][l,4]dioxin-2- yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- lH-pyrazole-4-carboxylate, (5)-2-(3-(4-((2,3- dihydrobenzo[b] [1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- 1H-pyrazol-4- yl)propan-2-ol, (S)- 1-(3-(4-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- lH-pyrazol-4-yl)pyrrolidin-2-one, (S)- 1-(3-(4-((2,3- dihydrobenzo[b] [1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,5-dimethyl- 1H-pyrazol-4-yl)-3 - methylimidazolidin-2-one, ( -N -(4-(4-((2,3-dihydrobenzo[b][l,4]dioxin-2- yl)methyl)piperazin- 1-yl)- 1,2,5-thiadiazol-3-yl)acetamide, (S)- 1-(4-(4-((2,3- dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,2,5-thiadiazol-3-yl)-3,3- dimethylpyrrolidin-2-one, (5)-4-(4-((2,3-dihydrobenzo[b][l,4]dioxin-2-yl)methyl)piperazin- 1-yl)-N -(pyrimidin-2-yl)- 1,2,5-thiadiazol-3-amine, (5)-4-(4-((2,3- dihydrobenzo[b][ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)-N -(pyrimidin-4-yl)- 1,2,5-thiadiazol 3-amine, (S)- 1-(5-(4-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)thiazol-4- yl)pyrrolidin-2-one, 1-(4-(4-(((5)-2,3-dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1- yl)- 1,2,5-thiadiazol-3-yl)-3-methylpyrrolidin-2-one, (5)-2-(4-((2,3- dihydrobenzo[b][l,4]dioxin-2-yl)methyl)piperazin-l-yl)-l,3,4-thiadiazole, (5)-3-(4-((2,3- dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)-5-(methoxymethyl)- 1,2,4- oxadiazole, (S)- 1-(4-(4-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,2,5- thiadiazol-3-yl)pyrrolidin-2-one, (S)-l-(5-(4-((2,3-dihydrobenzo[b][l,4]dioxin-2- yl)methyl)piperazin-l-yl)-l,3,4-thiadiazol-2-yl)imidazolidin-2-one, (5)-3-(4-(4-((2,3- dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,2,5-thiadiazol-3-yl)oxazoiidin-2- one, (5)-4-(4-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,2,5- thiadiazole-3-carboxamide, (S)- 1-(4-(4-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2- yl)methyl)piperazin- 1-yl)- 1,2,5-thiadiazol-3-yl)-3-methylimidazolidin-2-one, (5)-4-(4-((2,3- dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)-N-methyl- 1,2,5-thiadiazole-3- carboxamide hydrochloride, (S)- 1-(4-(4-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2- yl)methyl)piperazin- 1-yl)- 1,2,5-thiadiazol-3-yl)imidazolidin-2-one, (S)- 1-(5-(4-((2,3- dihydrobenzo[b] [1,4]dioxin-2-yl)methyl)piperazin- 1-yl)-3 -methylisothiazol-4-yl)pyrrolidin-2- one, (S)- 1-(4-(4-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)-2- methylthiazol-5-yl)-3,3-dimethylpyrrolidine-2,5-dione hydrochloride, (5)-l-(4-(4-((2,3- dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)- 1,2,5-thiadiazol-3-yl)ethanone, (5)- 4-(4-((2,3-dihydrobenzo[b] [ 1,4]dioxin-2-yl)methyl)piperazin- 1-yl)-N,N -dimethyl- 1,2,5- thiadiazole-3-carboxamide, (5)-4-(4-((2,3-dihydrobenzo[b][l,4]dioxin-2- yl)methyl)piperazin- 1-yl)-N -(pyridin-4-yl)- 1,2,5-thiadiazol-3-amine dihydrochloride, ( -3- (4-((2,3-dihydrobenzo[b][l,4]dioxin-2-yl)methyl)piperazin-l-yl)isothiazolo[4,5-b]pyridine hydrochloride, ( -N -(2-(benzyloxy)pyridin-3-yl)-4-(4-((2,3-dihydrobenzo[b][l,4]-dioxin-2- yl)methyl)piperazin- 1-yl)- 1,2,5-thiadiazol-3-amine hydrochloride, (S)- 1-((2,3- dihydrobenzo[b] [1,4]dioxin-2-yl)methyl)-4-(3 -methyl- 1-(pyridin-2-yl)- 1H-pyrazol-5 - yl)piperazine, (S)- 1-((2,3 -dihydrobenzo [b] [1,4] dioxin-2-yl)methyl)-4-( 1-(6-methoxypyridin- 2-yl)-3-methyl- 1H-pyrazol-5 -yl)piperazine, or (S)- 1-((2,3 -dihydrobenzo[b] [1,4] dioxin-2- yl)methyl)-4-(3 -methyl- 1-(6-methylpyridin-2-yl)- 1H-pyrazol-5 -yl)piperazine. 0. The compound according to claim 1, wherein the compound is or a pharmaceutically acceptable salt thereof. 11. The compound according to claim 1, wherein the compound is or a pharmaceutically acceptable salt thereof. 12. The compound according to claim 1, wherein the compound is or a pharmaceutically acceptable salt thereof. 13. The compound according to claim 1, wherein the compound or a pharmaceutically acceptable salt thereof. 4 . The compound according to claim 1, wherein the compound is or a pharmaceutically acceptable salt thereof. 15. The compound according to claim 1, wherein the compound is or a pharmaceutically acceptable salt thereof. 16. The compound according to claim 1, wherein the compound is or a pharmaceutically acceptable salt thereof. . The compound according to claim 1, wherein the compound is or a pharmaceutically acceptable salt thereof. 18. The compound according to claim 1, wherein the compound is or a pharmaceutically acceptable salt thereof. 19. The compound according to claim 1, wherein the compound is or a pharmaceutically acceptable salt thereof. 20. The compound according to claim 1, wherein the compound or a pharmaceutically acceptable salt thereof 2 1. The compound according to any one of claims 1 to 20 for use as a medicament. 22. The compound according to any one of claims 1 to 2 1 for use in the treatment of a disorder, condition, or disease where an alpha2C antagonist is indicated to be useful. 23. The compound according to claim 22, wherein the disorder, condition, or disease is a mental disorder propagated by stress, Parkinson's disease, depression, schizophrenia, attention deficit hyperactivity disorder, post-traumatic stress disorder, obsessive compulsive disorder, Tourette's syndrome, blepharospasm or other focal dystonias, temporal lobe epilepsy with psychosis, a drug-induced psychosis, Huntington's disease, a disorder caused by fluctuation of the levels of sex hormones, panic disorder, Alzheimer's disease or mild cognitive impairment. 24. A method for the treatment of a disorder, condition, or disease where an alpha2C antagonist is indicated to be useful, which method comprises administering to a mammal in need of such treatment an effective amount of at least one compound according to claim 1. 25. The method according to claim 24, wherein the disorder, condition, or disease is a mental disorder propagated by stress, Parkinson's disease, depression, schizophrenia, attention deficit hyperactivity disorder, post-traumatic stress disorder, obsessive compulsive disorder, Tourette's syndrome, blepharospasm or other focal dystonias, temporal lobe epilepsy with psychosis, a drug-induced psychosis, Huntington's disease, a disorder caused by fluctuation of the levels of sex hormones, panic disorder, Alzheimer's disease or mild cognitive impairment. 26. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 20 and a pharmaceutically acceptable carrier, diluent and/or excipient. 27. The pharmaceutical composition according to claim 26 wherein the composition comprises further at least one other active ingredient.